American Express Global Business Travel agrees to acquire Egencia from Expedia Group

American Express Global Business Travel agrees to acquire Egencia from Expedia Group

LONDON & SEATTLE–(BUSINESS WIRE)–
American Express Global Business Travel (GBT) has made a binding offer to acquire Egencia, Expedia Group’s corporate travel arm. As part of the transaction, Expedia Group would become a shareholder in, and enter a long-term strategic commercial agreement with, GBT.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210504005715/en/

The deal would bring Egencia, a leading digital travel management company, into the GBT family. GBT would continue to invest in the Egencia brand, its people and technology, as part of the world’s leading business travel platform.

Paul Abbott, GBT’s CEO, said: “Our strategy is to provide customers with unparalleled choice by having the best solutions for each managed travel segment that we serve. In Egencia, we would welcome the industry’s leading digital business travel platform.

“Egencia would be strengthened by GBT’s complementary technology, enterprise capabilities and cutting-edge content. This would create new opportunities for both multinational and small and medium-sized enterprise (SME) clients, suppliers and the talented teams within both organizations.”

Together, GBT and Egencia would offer comprehensive technology and customer solutions across every segment of business travel. Teaming Egencia with GBT’s Supply MarketPlace, one of the most comprehensive sources for content and experiences for business travelers, would give customers more choice and suppliers more access to business travelers.

Meanwhile, with both the Egencia platform and GBT’s Neo Technology Group, the business would be positioned to build the best solutions for the future of business travel.

President of Expedia Business Services Ariane Gorin said: “We are thrilled by the potential transaction and what GBT and Egencia could achieve together, as Expedia Group seeks to simplify our business and be a leader in all of our endeavours. The combination of GBT’s leading solutions with Egencia’s great technology and team would help create the world’s best business travel offerings for customers and suppliers.

“At the same time, a greatly expanded, long-term accommodations supply agreement with Expedia Partner Solutions (EPS) would enhance GBT’s Supply MarketPlace and meaningfully further Expedia Group’s goal of powering businesses across the entire eco-system.

“Expedia Group strongly believes in the robust return of travel, including in the corporate space. We’re excited about our potential ownership in GBT and our long-term arrangement to power Egencia and GBT, as we do for thousands of other travel companies,” Gorin added.

The proposed deal is subject to consultation by Expedia Group and Egencia with their applicable employee representatives, as well as customary closing conditions including regulatory approvals.

About American Express Global Business Travel

American Express Global Business Travel (GBT) is the world’s leading business partner for managed travel. We help companies and their employees prosper by making sure travellers are present where and when it matters. We keep global business moving with the powerful backing of travel professionals in more than 140 countries. Companies of all sizes, and in all places, rely on GBT to provide travel management services, organise meetings and events, and deliver business travel consulting.

Visit amexglobalbusinesstravel.com for more information about GBT, and follow @amexgbt on Twitter, LinkedIn and Instagram.

About Expedia Group

Expedia Group, Inc. (NASDAQ: EXPE) companies power travel for everyone, everywhere through our global platform. Driven by the core belief that travel is a force for good, we help people experience the world in new ways and build lasting connections. We provide industry-leading technology solutions to fuel partner growth and success, while facilitating memorable experiences for travelers. The Expedia Group family of brands includes: Expedia®, Hotels.com®, Expedia® Partner Solutions, Vrbo®, Egencia®, trivago®, Orbitz®, Travelocity®, Hotwire®, Wotif®, ebookers®, CheapTickets®, Expedia Group™ Media Solutions, Expedia Local Expert®, CarRentals.com™, and Expedia Cruises™.

© 2021 Expedia, Inc., an Expedia Group company. All rights reserved. Trademarks and logos are the property of their respective owners. CST: 2029030-50

American Express Global Business

KWT Global

[email protected]

+1 929-358-4068

Expedia Group press contact:

[email protected]

KEYWORDS: Europe United States United Kingdom North America Washington

INDUSTRY KEYWORDS: Technology Public Relations/Investor Relations Communications Software Other Travel Destinations Data Management Vacation Travel

MEDIA:

Logo
Logo
Logo
Logo

Sesen Bio Announces Commercial Launch Readiness Progress as the Company Approaches the Potential Approval and Launch of Vicineum™

Sesen Bio Announces Commercial Launch Readiness Progress as the Company Approaches the Potential Approval and Launch of Vicineum™

Company appoints experienced commercial leader, Lisa LaMond, to oversee sales strategy and execution

Selected Syneos Health® as partner for field sales execution in the US

Company remains on track for potential approval in the US in August 2021

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the expansion of its leadership team with the appointment of experienced commercial industry leader, Lisa LaMond, as Vice President, Sales and Corporate Systems. The Company also announced its engagement of leading contract sales organization (CSO), Syneos Health, for field sales support and execution in the US for Vicineum.

Lisa LaMond brings invaluable experience in commercial pharmaceuticals to her role as Vice President, Sales and Corporate Systems. Prior to joining Sesen Bio, Ms. LaMond spent her career at Merck & Co. Inc. where she developed a diverse skillset across key commercial functions, as well as a deep understanding of the evolving healthcare environment and customer landscapes. Early in her Merck career, Ms. LaMond led large organizations and launched several innovative, FDA-approved products and a number of new initiatives that transformed the growth and strength of diverse geographical markets. She also held various leadership positions in sales, launch strategy, marketing, account management, risk management, and policy. At every level, she excelled at building new capabilities as well as developing strategy and priorities to drive execution for commercial success. Ms. LaMond holds a Bachelor of Science degree from California State University in Long Beach, CA, and earned her Masters of Business Administration from University of Redlands.

“I am delighted to welcome Lisa to the Sesen Bio senior leadership team,” said Dr. Thomas Cannell, president and chief executive officer of Sesen Bio. “Lisa’s many accomplishments over her career embody our mission to save and improve the lives of patients, and her extensive commercial experience will be critical in the development and oversight of our sales strategy and execution.”

Syneos Health has deep expertise in Urology and Uro-oncology with specific experience supporting first product launches in biopharmaceutical organizations. Syneos Health will provide comprehensive support for the sales organization including sales force logistics, hiring and deployment of key talent and sales force operations. The sales force will include 35 sales representatives across four regions to target approximately 2,000 high prescribers of BCG.

“We believe Syneos Health is the strongest CSO organization in the US and will help us quickly hire and manage the sales force,” continued Dr. Cannell. “I have a lot of confidence that with Lisa’s leadership and the ability of Syneos to execute, together we can build a sales organization capable of delivering a world-class launch of Vicineum, if approved, in August this year.”

In connection with the hiring of Lisa LaMond, non-statutory stock options were granted. Under the grant of non-statutory stock options, up to 250,000 shares of Sesen Bio common stock are purchasable upon vesting of the stock options within the ten-year term. The stock options vest over a four-year period, with one quarter of the underlying shares vesting on the first anniversary of the date of grant, and an additional 6.25% of the underlying shares vesting at the end of each successive three-month period following the one-year anniversary of the date of grant, subject to Ms. LaMond’s continued service with Sesen Bio.

The non-statutory stock options were granted on May 3, 2021 at an exercise price equal to the closing price per share of Sesen Bio’s common stock on The Nasdaq Global Market on the date of grant. The stock options were granted outside of the Company’s 2014 Stock Incentive Plan and were granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

About Vicineum™

Vicineum, a locally administered fusion protein, is Sesen Bio’s lead product candidate being developed for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Vicineum is comprised of a recombinant fusion protein that targets epithelial cell adhesion molecule (EpCAM) antigens on the surface of tumor cells to deliver a potent protein payload, Pseudomonas Exotoxin A. Vicineum is constructed with a stable, genetically engineered peptide tether to ensure the payload remains attached until it is internalized by the cancer cell, which is believed to decrease the risk of toxicity to healthy tissues, thereby improving its safety. In prior clinical trials conducted by Sesen Bio, EpCAM has been shown to be overexpressed in NMIBC cells with minimal to no EpCAM expression observed on normal bladder cells. Sesen Bio is currently in the follow-up stage of a Phase 3 registration trial in the US for the treatment of BCG-unresponsive NMIBC. In February 2021, the FDA accepted for filing the Company’s BLA for Vicineum for the treatment of BCG-unresponsive NMIBC and granted the application Priority Review with a target PDUFA date of August 18, 2021. Additionally, Sesen Bio believes that cancer cell-killing properties of Vicineum promote an anti-tumor immune response that may potentially combine well with immuno-oncology drugs, such as checkpoint inhibitors. For this reason, the activity of Vicineum in BCG-unresponsive NMIBC is also being explored at the US National Cancer Institute in combination with AstraZeneca’s immune checkpoint inhibitor durvalumab.

About Sesen Bio

Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company’s lead program, Vicineum™, also known as oportuzumab monatox, is currently in the follow-up stage of a Phase 3 registration trial for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). In February 2021, the FDA accepted for filing the Company’s BLA for Vicineum for the treatment of BCG-unresponsive NMIBC and granted the application Priority Review with a target PDUFA date of August 18, 2021. Sesen Bio retains worldwide rights to Vicineum with the exception of Greater China and the Middle East and North Africa (MENA), for which the Company has partnered with Qilu Pharmaceutical and Hikma Pharmaceuticals, respectively, for commercialization. Vicineum is a locally administered targeted fusion protein composed of an anti-EpCAM antibody fragment tethered to a truncated form of Pseudomonas Exotoxin A for the treatment of BCG-unresponsive NMIBC. For more information, please visit the Company’s website at www.sesenbio.com.

COVID-19 Pandemic Potential Impact

Sesen Bio continues to monitor the rapidly evolving environment regarding the potential impact of the COVID-19 pandemic on the Company. The Company has not yet experienced any disruptions to our operations as a result of COVID-19, however, we are not able to quantify or predict with certainty the overall scope of potential impacts to our business, including, but not limited to, our ability to raise capital and, if approved, commercialize Vicineum. Sesen Bio remains committed to the health and safety of patients, caregivers and employees.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the Company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the timing for the FDA’s decision on the Company’s BLA for Vicineum for the treatment of BCG-unresponsive NMIBC based on the FDA granting the BLA Priority Review, the target PDUFA date of August 18, 2021 and the need for an advisory meeting on the BLA, the development and oversight of the Company sales strategy and execution and the Company’s ability to hire and manage a sales force to launch Vicineum, if approved, the impact of COVID-19 on the Company, including its ability to raise capital, and, if approved, its ability to commercialize Vicineum for the treatment of BCG-unresponsive NMIBC, and other factors discussed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other reports filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.

Erin Clark, Vice President, Corporate Strategy & Investor Relations

[email protected]

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Biotechnology Health Pharmaceutical Clinical Trials Oncology

MEDIA:

Logo
Logo

Sysco Reports Third Quarter Fiscal 2021 Results

U.S. Recovery Accelerating; Sysco Now Serving More Independent Customers Than in 2019 While Executing Transformation; Significant Debt Reduction Underway

HOUSTON, May 04, 2021 (GLOBE NEWSWIRE) — Sysco Corporation (NYSE: SYY) today announced financial results for its 13-week third fiscal quarter ended March 27, 2021.

  • Sales trends improving as markets reopen; Q3 decreased 13.7% versus FY20 and decreased 19.3% versus FY19; April increased 102.1% versus 2020 and decreased 8.8% versus 2019;
  • We are now serving more independent customers compared to pre-COVID;
  • Gross profit decreased 17.2% to $2.1 billion; industry-leading gross margin decreased 77 basis points on mix among businesses;
  • Operating income increased 291.4% to $235.9 million; adjusted1 operating income decreased 32.0% to $256.2 million;
  • Earnings before interest, taxes, depreciation and amortization (“EBITDA”) increased 76.5% to $425.8 million; adjusted1 EBITDA decreased 18.7% to $437.4 million;
  • Earnings per share (“EPS”) increased $0.18, to $0.17; adjusted1 EPS decreased $0.23, to $0.22;
  • Cash flow from operations was $543.1 million and free cash flow was $459.7 million in the quarter; and
  • Company reduced debt by $1.1 billion during the quarter.

“A robust business recovery is now upon us. We are seeing consistently improving demand trends from our customers in the United States and we are ready to execute in International as markets reopen,” said Kevin Hourican, Sysco’s president and chief executive officer. “Sysco has made substantial progress against our transformation agenda, as we simultaneously invest in growth and transform our company to better serve our customers.”

1
Earnings Per Share (EPS) are shown on a
diluted basis unless otherwise specified. Adjusted financial results exclude certain items, which primarily include adjustments to our bad debt reserve specific to aged receivables existing prior to the COVID-19 pandemic, goodwill impairment charges, restr
ucturing costs, transformational project costs and acquisition-related costs. Specific to EPS, this year’s third quarter and first 39 weeks Certain Items include the impact of a loss on the sale of our Spain operations. The first 39 weeks Certain Items inc
lude the impact of a loss on the sale of Cake Corporation and the impact of a new U.K. tax law change. Reconciliations of all non-GAAP measures are included at the end of this release.

Third Quarter Fiscal 2021 Results

Total Sysco

Sales for the third quarter were $11.8 billion, a decrease of 13.7% compared to the same period last year. The exit rate for the third quarter was stronger than the overall quarter, as select geographic markets continue to drive the recovery as restrictions ease in the areas in which we operate.

Gross profit decreased 17.2% to $2.1 billion, and gross margin decreased 77 basis points to 18.0%, compared in each case to the same period last year. The decline in gross profit for the third quarter was primarily driven by lower volumes due to COVID-19.

Operating expenses decreased $617.2 million, or 24.6%, compared to the same period last year, driven by reduced costs from the achievement of cost-out initiatives, as well as a benefit from a reduction in our allowance for doubtful accounts. Adjusted operating expenses decreased $320.8 million, or 14.7%, compared to the same period last year.

Operating income was $235.9 million, an increase of $175.6 million, or 291.4%, compared to the same period last year. Adjusted operating income was $256.2 million, a decrease of $120.8 million, or 32.0%, compared to the same period last year.

“We are leveraging our balance sheet strength to invest in our business – inventory, fleet, people and technology — while simultaneously reducing our debt levels to reflect the improving business environment,” said Aaron Alt, Sysco’s chief financial officer.

U.S. Foodservice Operations

Sales for the third quarter were $8.4 billion, a decrease of 12.8% compared to the same period last year. Local case volume within U.S. Broadline operations decreased 9.7% for the third quarter, of which a decrease of 9.7% was organic, while total case volume within U.S. Broadline operations decreased 14.1%, of which a decrease of 14.1% was organic.

Gross profit decreased 13.7% to $1.6 billion, and gross margin decreased 22 basis points to 19.6%, compared in each case to the same period last year. Product cost inflation was 3.5% in U.S. Broadline, as measured by the estimated change in Sysco’s product costs, primarily in the paper and disposables, poultry, and meat categories.

Operating expenses decreased $341.9 million, or 23.9%, compared to the same period last year. Adjusted operating expenses decreased $212.9 million, or 16.1%, compared to the same period last year.

Operating income was $545.5 million, an increase of $81.3 million, or 17.5%, compared to the same period last year. Adjusted operating income was $525.1 million, a decrease of $47.7 million, or 8.3%, compared to the same period last year.

International Foodservice Operations

Sales for the third quarter were $1.7 billion, a decrease of 31.3% compared to the same period last year. On a constant currency basis, sales for the third quarter were $1.6 billion, a decrease of 35.4% compared to the same period last year. Foreign exchange rates increased International Foodservice Operations sales by 4.1% and total Sysco sales by 0.8% during the quarter.

Gross profit decreased 35.1% to $325.2 million, and gross margin decreased 110 basis points to 18.9%, compared in each case to the same period last year. On a constant currency basis, gross profit decreased 39.2% to $304.5 million. Foreign exchange rates increased International Foodservice Operations gross profit by 4.1% and total Sysco gross profit by 0.8% during the quarter.

Operating expenses decreased $138.0 million, or 23.6%, compared to the same period last year. Adjusted operating expenses decreased $78.4 million, or 15.8%, compared to the same period last year. On a constant currency basis, adjusted operating expenses decreased $107.2 million, or 21.6%, compared to the same period last year. Foreign exchange rates increased International Foodservice Operations operating expense by 5.8% and total Sysco operating expense by 1.3% during the quarter.

The International Foodservice Operations segment delivered an operating loss of $121.5 million, a decrease of $37.7 million compared to the same period last year. Adjusted operating loss was $92.4 million, a decrease of $97.4 million compared to the same period last year. On a constant currency basis, adjusted operating loss was $84.2 million, a decrease of $89.2 million compared to the same period last year. Foreign exchange rates increased International Foodservice Operations operating loss by $8.2 million and reduced total Sysco operating income by $8.0 million during the quarter.


Balance Sheet, Capital Spending and Cash Flow

Capital expenditures, net of proceeds from sales of plant and equipment, for the first 39 weeks of fiscal 2021 were $358.8 million lower compared to the prior year period.

Cash flow from operations was $1.5 billion for the first 39 weeks of fiscal 2021, which was $401.3 million higher compared to the prior year period. Free cash flow2 for the first 39 weeks of fiscal 2021 was $1.2 billion, which was $760.1 million higher compared to the prior year period. The improvement in cash flow was driven by higher earnings, improved working capital, lower capital spending and lower cash taxes paid during the quarter.

2
Free cash flow is a non-GAAP measure that represents net cash provide
d from operating activities less purchases of plant and equipment and includes proceeds from sales of plant and equipment. Reconciliations for all non-GAAP measures are included at the end of this release.


Conference Call & Webcast

Sysco will host a conference call to review the company’s third quarter fiscal 2021 financial results on Tuesday, May 4, 2021, at 10:00 a.m. Eastern. A live webcast of the call, accompanying slide presentation and a copy of this news release will be available online at investors.sysco.com.

Key Highlights:

  13-Week Period Ended 39-Week Period Ended
         
 Financial Comparison: March 27, 2021 Change March 27, 2021 Change
 Sales $11.8 billion -13.7% $35.2 billion -20.1%
 Gross profit $2.1 billion -17.2% $6.4 billion -22.7%
 Gross Margin 18.0
%
-77 bps 18.3
%
-62 bps
         
 GAAP:        
 Operating expenses $1.9 billion -24.6% $5.6 billion -21.0%
Certain Items $20.3 million -93.6
%
$(12.6) million -102.7
%
 Operating Income $235.9 million 291.4% $867.6 million -32.3%
 Operating Margin 2.0
%
156 bps 2.5
%
-44 bps
 Net Earnings $88.9 million NM $373.1 million -55.3%
 Diluted Earnings Per Share $0.17 NM $0.73 -54.9%
         
 Non-GAAP

(1)

:
       
 Operating Expenses $1.9 billion -14.7% $5.6 billion -15.2%
 Operating Income $256.2 million -32.0% $855.0 million -51.0%
 Operating Margin 2.2
%
-59 bps 2.4
%
-153 bps
 EBITDA $425.8 million 76.5% $1.4 billion -22.3%
 Adjusted EBITDA $437.4 million -18.7% $1.4 billion -38.3%
 Net Earnings $114.8 million -50.5% $374.1 million -68.3%
 Diluted Earnings Per Share (2) $0.22 -51.1% $0.73 -68.1%
         
 Case Growth:        
U.S. Broadline -14.1%   -21.4%  
Local -9.7
%
  -17.2
%
 
         
 Sysco Brand Sales as a % of Cases:        
U.S. Broadline 37.3% -116 bps 37.6% -92 bps
Local 44.5
%
-234 bps 44.4
%
-274 bps

Note:

(1) A reconciliation of non-GAAP measures is included at the end of this release.
(2) Individual components in the table above may not sum to the totals due to the rounding.
NM represents that the percentage change is not meaningful.

Forward-Looking Statements

Statements made in this press release or in our earnings call for the third quarter of fiscal 2021 that look forward in time or that express management’s beliefs, expectations or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the views of management at the time such statements are made and are subject to a number of risks, uncertainties, estimates, and assumptions that may cause actual results to differ materially from current expectations. These statements include statements concerning: the effect, impact, potential duration or other implications of the coronavirus (“COVID-19”) pandemic and any expectations we may have with respect thereto, including the extent and duration of lockdowns in the U.S. and Europe; the pace of the business recovery; our expectations regarding our ability to manage the current downturn and capitalize on our position as the industry leader as the global economy recovers; our expectations regarding future market share gains; the pace of implementation of our business transformation initiatives; our belief that our strategy and our transformational initiatives will drive future value for our associates, shareholders and customers in the fourth quarter and beyond; our expectations regarding our company, and our ability to attract and serve new customers, following the COVID-19 crisis; our expectations regarding our ability to win meaningful business in the national account space; the effects of our continuing investments in digital technology; our expectations regarding the timing of the business recovery following the COVID-19 crisis; our belief that consumers are ready to eat at restaurants as soon as COVID-19 restrictions are reduced; our expectations regarding the business recovery in Europe; the impact on our results of government-imposed restrictions on restaurant operations; our expectations that our work to accelerate growth will return to pre-COVID levels as demand resurges; our expectations regarding the effect of our hiring of drivers on transportation expenses in the short term; our belief that our hiring of drivers will help ensure that Sysco is able to maximize our share gain during the upcoming business recovery; our expectations regarding our ability to become the most customer-centric foodservice distributor in the industry; our expectations regarding our ability to accelerate profitable growth; our expectations regarding future sales; our expectations regarding cost savings over the next several quarters; our expectations that our investments in technology and our business will allow for future growth and exceptional customer service; our belief that the steps undertaken as part of our management of the COVID-19 crisis to date will help us retain and win additional business from our independent restaurant customers beyond the pandemic; our expectations that we will hire over 6,000 associates in the second half of our fiscal year; our expectations of significant returns on our investments in our capability builds in service of our transformation; our expectations regarding the impact of our investments in our transformation initiatives on our results in the second half of fiscal 2021; our expectations regarding improvements in the SYGMA segment; our plans to transition away from a large existing SYGMA customer; our expectations that international will be a growth opportunity for Sysco in fiscal 2022; our plans to reinvest a portion of our cost savings into our growth agenda; our ability to deliver against our strategic priorities; statements regarding economic trends in the United States and abroad; our expected repayment of amounts under the UK Commercial Paper Program; our expectations regarding the deployment of capital proceeds that Sysco currently holds; and our expectations regarding our cash performance in the fourth quarter of fiscal 2021.

The success of our plans and expectations regarding our operating performance are subject to the general risks associated with our business, including the risks of interruption of supplies due to lack of long-term contracts, severe weather, crop conditions, work stoppages, intense competition, technology disruptions, dependence on large, long-term regional and national customers, inflation risks, the impact of fuel prices, adverse publicity, labor issues, political or financial instability, trade restrictions, tariffs, currency exchange rates, transport capacity and costs and other factors relating to foreign trade, any or all of which could delay our receipt of product or increase our input costs. Risks and uncertainties also include the impact and effects of public health crises, pandemics and epidemics, such as the COVID-19 pandemic, and the adverse impact thereof on our business, financial condition and results of operations, including, but not limited to, our growth, product costs, supply chain, labor availability, logistical capabilities, customer demand for our products and industry demand generally, consumer spending, our liquidity, the price of our securities and trading markets with respect thereto, our credit ratings, our ability to maintain compliance with the covenants in our credit agreement, our ability to access capital markets, and the global economy and financial markets generally. Risks and uncertainties also include risks impacting the economy generally, including the risks that the current general economic conditions will deteriorate, or consumer confidence in the economy or consumer spending, particularly on food-away-from-home, may decline. Market conditions may not improve. Competition and the impact of GPOs may reduce our margins and make it difficult for us to maintain our market share, growth rate and profitability. We may not be able to fully compensate for increases in fuel costs, and fuel hedging arrangements intended to contain fuel costs could result in above market fuel costs. Our ability to meet our long-term strategic objectives depends on our ability to grow gross profit, leverage our supply chain costs and reduce administrative costs. This will depend largely on the success of our various business initiatives, including efforts related to revenue management, expense management, our digital e-commerce strategy and any efforts related to restructuring or the reduction of administrative costs. There are various risks related to these efforts, including the risk that if sales from our locally managed customers do not grow at the same rate as sales from regional and national customers, or if we are unable to continue to accelerate local case growth, our gross margins may decline; the risk that we are unlikely to be able to predict inflation over the long term, and lower inflation is likely to produce lower gross profit; the risk that our efforts to mitigate increases in warehouse costs may be unsuccessful; the risk that we may not be able to accelerate and/or identify additional administrative cost savings in order to compensate for any gross profit or supply chain cost leverage challenges; the risk that these efforts may not provide the expected benefits in our anticipated time frame, if at all, and may prove costlier than expected; the risk that the actual costs of any initiatives may be greater or less than currently expected; and the risk of adverse effects to our business, results of operations and liquidity if past and future undertakings, and the associated changes to our business, do not prove to be cost effective or do not result in the cost savings and other benefits at the levels that we anticipate. Our plans related to and the timing of any initiatives are subject to change at any time based on management’s subjective evaluation of our overall business needs. If we are unable to realize the anticipated benefits from our efforts, we could become cost disadvantaged in the marketplace, and our competitiveness and our profitability could decrease. Adverse publicity about us or lack of confidence in our products could negatively impact our reputation and reduce earnings. Capital expenditures may vary based on changes in business plans and other factors, including risks related to the implementation of various initiatives, the timing and successful completion of acquisitions, construction schedules and the possibility that other cash requirements could result in delays or cancellations of capital spending. Periods of significant or prolonged inflation or deflation, either overall or in certain product categories, can have a negative impact on us and our customers, as high food costs can reduce consumer spending in the food-away-from-home market, and may negatively impact our sales, gross profit, operating income and earnings, and periods of deflation can be difficult to manage effectively. Fluctuations in inflation and deflation, as well as fluctuations in the value of foreign currencies, are beyond our control and subject to broader market forces. Expanding into international markets presents unique challenges and risks, including compliance with local laws, regulations and customs and the impact of local political and economic conditions, including the impact of Brexit and the “yellow vest” protests in France against a fuel tax increase, pension reform and the French government, and such expansion efforts may not be successful. Any business that we acquire may not perform as expected, and we may not realize the anticipated benefits of our acquisitions. Expectations regarding the financial statement impact of any acquisitions may change based on management’s subjective evaluation. A divestiture of one or more of our businesses may not provide the anticipated effects on our operations. Meeting our dividend target objectives depends on our level of earnings, available cash and the success of our various strategic initiatives. Changes in applicable tax laws or regulations and the resolution of tax disputes could negatively affect our financial results. We rely on technology in our business and any cybersecurity incident, other technology disruption or delay in implementing new technology could negatively affect our business and our relationships with customers. For a discussion of additional factors impacting Sysco’s business, see our Annual Report on Form 10-K for the year ended June 27, 2020, as filed with the SEC, and our subsequent filings with the SEC. We do not undertake to update our forward-looking statements, except as required by applicable law.


About Sysco

Sysco is the global leader in selling, marketing and distributing food products to restaurants, healthcare and educational facilities, lodging establishments and other customers who prepare meals away from home. Its family of products also includes equipment and supplies for the foodservice and hospitality industries. With more than 57,000 associates, the company operates 326 distribution facilities worldwide and serves more than 625,000 customer locations. For fiscal 2020 that ended June 27, 2020, the company generated sales of more than $52 billion. Information about our CSR program, including Sysco’s 2020 Corporate Social Responsibility Report, can be found at sysco.com/csr2020report.

For more information, visit www.sysco.com or connect with Sysco on Facebook at www.facebook.com/SyscoFoods. For important news and information regarding Sysco, visit the Investor Relations section of the company’s Internet home page at investors.sysco.com, which Sysco plans to use as a primary channel for publishing key information to its investors, some of which may contain material and previously non-public information. In addition, investors should continue to review our news releases and filings with the SEC. It is possible that the information we disclose through any of these channels of distribution could be deemed to be material information.

Sysco Corporation and its Consolidated Subsidiaries

CONSOLIDATED RESULTS OF OPERATIONS

(In Thousands, Except for Share and Per Share Data)

  13-Week Period Ended   39-Week Period Ended
  Mar. 27, 2021   Mar. 28, 2020   Mar. 27, 2021   Mar. 28, 2020
               
Sales $ 11,824,589     $ 13,698,699     $ 35,160,950     $ 44,026,746  
Cost of sales 9,701,921     11,134,459     28,719,979     35,690,737  
Gross profit 2,122,668     2,564,240     6,440,971     8,336,009  
Operating expenses 1,886,751     2,503,966     5,573,413     7,054,924  
Operating income 235,917     60,274     867,558     1,281,085  
Interest expense 145,773     83,854     438,988     243,951  
Other (income) expense, net (12,708 )   5,200     (14,140 )   7,505  
Earnings (loss) before income taxes 102,852     (28,780 )   442,710     1,029,629  
Income taxes 13,925     (25,483 )   69,594     195,735  
Net earnings (loss) $ 88,927     $ (3,297 )   $ 373,116     $ 833,894  
               
Net earnings (loss):              
Basic earnings (loss) per share $ 0.17     $ (0.01 )   $ 0.73     $ 1.63  
Diluted earnings (loss) per share 0.17     (0.01 )   0.73     1.62  
               
Average shares outstanding 511,110,670     508,745,253     510,081,610     510,729,277  
Diluted shares outstanding 514,585,129     512,657,657     512,688,895     515,632,815  



Sysco Corporation and its Consolidated Subsidiaries

CONSOLIDATED BALANCE SHEETS

(In Thousands, Except for Share Data)

  Mar. 27, 2021   Jun. 27, 2020
       
ASSETS
Current assets      
Cash and cash equivalents $ 4,895,723     $ 6,059,427  
Accounts receivable, less allowances of $211,607 and $334,810 3,220,659     2,893,551  
Inventories 3,218,827     3,095,085  
Prepaid expenses and other current assets 250,022     192,163  
Income tax receivable 1,534     108,006  
Total current assets 11,586,765     12,348,232  
Plant and equipment at cost, less accumulated depreciation 4,297,862     4,458,567  
Other long-term assets      
Goodwill 3,932,570     3,732,469  
Intangibles, less amortization 769,503     780,172  
Deferred income taxes 321,674     194,115  
Operating lease right-of-use assets, net 661,474     603,616  
Other assets 473,433     511,095  
Total other long-term assets 6,158,654     5,821,467  
Total assets $ 22,043,281     $ 22,628,266  
       
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities      
Notes payable $ 8,315     $ 2,266  
Accounts payable 4,221,252     3,447,065  
Accrued expenses 1,645,139     1,616,289  
Accrued income taxes 64,159     2,938  
Current operating lease liabilities 111,761     107,167  
Current maturities of long-term debt 957,303     1,542,128  
Total current liabilities 7,007,929     6,717,853  
Long-term liabilities      
Long-term debt 11,741,114     12,902,485  
Deferred income taxes 49,426     86,601  
Long-term operating lease liabilities 586,479     523,496  
Other long-term liabilities 1,228,265     1,204,953  
Total long-term liabilities 13,605,284     14,717,535  
Commitments and contingencies      
Noncontrolling interest 34,471     34,265  
Shareholders’ equity      
Preferred stock, par value $1 per share Authorized 1,500,000 shares, issued none      
Common stock, par value $1 per share Authorized 2,000,000,000 shares, issued
765,174,900 shares
765,175     765,175  
Paid-in capital 1,594,561     1,506,901  
Retained earnings 10,241,666     10,563,008  
Accumulated other comprehensive loss (1,352,446 )   (1,710,881 )
Treasury stock at cost, 253,817,013 and 256,915,825 shares (9,853,359 )   (9,965,590 )
Total shareholders’ equity 1,395,597     1,158,613  
Total liabilities and shareholders’ equity $ 22,043,281     $ 22,628,266  



Sysco Corporation and its Consolidated Subsidiaries

CONSOLIDATED CASH FLOWS

(In Thousands)

  39-Week Period Ended
  Mar. 27, 2021   Mar. 28, 2020
Cash flows from operating activities:      
Net earnings $ 373,116     $ 833,894  
Adjustments to reconcile net earnings to cash provided by operating activities:      
Share-based compensation expense 65,655     63,942  
Depreciation and amortization 542,471     558,588  
Operating lease asset amortization 81,414     83,749  
Amortization of debt issuance and other debt-related costs 19,485     15,247  
Goodwill impairment     68,725  
Deferred income taxes (161,824 )   (145,133 )
Provision for losses on receivables (137,670 )   213,769  
Loss on sale of businesses 22,834      
Other non-cash items (7,507 )   6,765  
Additional changes in certain assets and liabilities, net of effect of businesses acquired:      
(Increase) decrease in receivables (130,403 )   342,557  
Increase in inventories (82,525 )   (497,391 )
Increase in prepaid expenses and other current assets (50,833 )   (38,831 )
Increase (decrease) in accounts payable 800,248     (353,836 )
Increase (decrease) in accrued expenses 9,065     (28,406 )
Decrease in operating lease liabilities (94,228 )   (95,861 )
Increase (decrease) in accrued income taxes 167,693     (25,987 )
Decrease in other assets 23,345     23,263  
Increase in other long-term liabilities 39,448     53,415  
Net cash provided by operating activities 1,479,784     1,078,469  
       
Cash flows from investing activities:      
Additions to plant and equipment (251,167 )   (603,865 )
Proceeds from sales of plant and equipment 19,308     13,245  
Acquisition of businesses, net of cash acquired     (142,780 )
Purchase of marketable securities (44,687 )   (11,424 )
Proceeds from sales of marketable securities 30,773     17,465  
Other investing activities     67,371  
Net cash used for investing activities (245,773 )   (659,988 )
       
Cash flows from financing activities:      
Bank and commercial paper (repayments) borrowings, net (411,200 )   20,886  
Other debt borrowings 2,943     2,682,278  
Other debt repayments (1,489,431 )   (28,244 )
Proceeds from stock option exercises 112,231     186,503  
Stock repurchases     (844,699 )
Dividends paid (689,251 )   (628,056 )
Other financing activities (1) (15,024 )   (45,990 )
Net cash (used for) provided by financing activities (2,489,732 )   1,342,678  
       
Effect of exchange rates on cash, cash equivalents and restricted cash 85,183     (8,857 )
       
Net (decrease) increase in cash and cash equivalents (2) (1,170,538 )   1,752,302  
Cash, cash equivalents and restricted cash at beginning of period 6,095,570     532,245  
Cash, cash equivalents and restricted cash at end of period (2) $ 4,925,032     $ 2,284,547  
       
Supplemental disclosures of cash flow information:      
Cash paid during the period for:      
Interest $ 386,753     $ 247,606  
Income taxes, net of refunds 71,435     358,622  

(1)  Change includes cash paid for shares withheld to cover taxes, debt issuance costs and other financing activities.
(2)  Change includes restricted cash included within other assets in the Consolidated Balance Sheet.

Sysco Corporation and its Consolidated Subsidiaries

Non-GAAP Reconciliation (Unaudited)

Impact of Certain Items

Sysco’s results of operations for fiscal 2021 and fiscal 2020 were impacted by restructuring and transformational project costs consisting of: (1) restructuring charges; (2) expenses associated with our various transformation initiatives; and (3) facility closure and severance charges. Sysco’s results for fiscal 2021 and fiscal 2020 were also impacted by intangible amortization expense related to the fiscal 2017 acquisition of Cucina Lux Investments Limited (the Brakes Acquisition). Additionally, our results for fiscal 2021 were impacted by loss on the sale of businesses.

Fiscal 2021 results of operations were also positively impacted by the reduction of bad debt expense previously recognized in fiscal 2020 due to the unexpected impact of the COVID-19 pandemic on the collectability of our pre-pandemic trade receivable balances. Fiscal 2020 results of operations were also negatively impacted by costs arising from the COVID-19 pandemic, the most significant of which were (1) excess bad debt expense, as we experienced an increase in past due receivables and recognized additional bad debt charges, and (2) goodwill impairment charges. Many of Sysco’s customers, including those in the restaurant, hospitality and education segments, are operating at a substantially reduced volume due to governmental requirements for closures or other social-distancing measures and a portion of Sysco’s customers have been closed. Some of these customers ceased paying their outstanding receivables, creating uncertainty as to their collectability. We experienced an increase in past due receivables and recognized additional bad debt charges in the third and fourth quarters of fiscal 2020; however, collections have improved in fiscal 2021, partially from restaurant reopenings, volumes improvements and Sysco’s improved credit processes. We have estimated uncollectible amounts based on the current collection experience and by applying write-off percentages based on historical loss experience, including loss experience during times of local and regional disasters, current conditions and collection rates, and expectations regarding future losses. The COVID-19 pandemic is more widespread and longer in duration than historical disasters impacting our business, and it is possible that actual uncollectible amounts will differ and additional charges may be required; however, if collections continue to improve, it is also possible that additional reductions in our bad debt reserve could occur. While Sysco traditionally incurs bad debt expense, the magnitude of such expenses and benefits, that we have experienced is not indicative of our normal operations. Our adjusted results have not been normalized in a manner that would exclude the full impact of the COVID-19 pandemic on our business. As such, Sysco has not adjusted its results for lost sales, inventory write-offs or other costs associated with the COVID-19 pandemic not previously stated.

The results of our foreign operations can be impacted due to changes in exchange rates applicable in converting local currencies to U.S. dollars. We measure our total Sysco and our International Foodservice Operations results on a constant currency basis. Constant currency operating results are calculated by translating current-period local currency operating results with the currency exchange rates used to translate the financial statements in the comparable prior-year period to determine what the current-period U.S. dollar operating results would have been if the currency exchange rate had not changed from the comparable prior-year period. The constant currency impact on our adjusted total Sysco and our adjusted International Foodservice Operations results are disclosed when the impact exceeds a defined threshold of greater than 1% on the growth metric. If the amount does not exceed this threshold, a disclosure will be made that the impact of the currency change was not significant.

Management believes that adjusting its operating expenses, operating income, net earnings and diluted earnings per share to remove these Certain Items and presenting its International Foodservice Operations results on a constant currency basis, provides an important perspective with respect to our underlying business trends and results and provides meaningful supplemental information to both management and investors that (1) is indicative of the performance of the company’s underlying operations and (2) facilitates comparisons on a year-over-year basis.

Although Sysco has a history of growth through acquisitions, the Brakes Group was significantly larger than the companies historically acquired by Sysco, with a proportionately greater impact on Sysco’s consolidated financial statements. Accordingly, Sysco is excluding from its non-GAAP financial measures for the relevant period the impact of acquisition-related intangible amortization specific to the Brakes Acquisition. We believe this approach significantly enhances the comparability of Sysco’s results for fiscal 2021 and fiscal 2020.

Set forth below is a reconciliation of sales, operating expenses, operating income, interest expense, other (income) expense, net earnings and diluted earnings per share to adjusted results for these measures for the periods presented. Individual components of diluted earnings per share may not add up to the total presented due to rounding. Adjusted diluted earnings per share is calculated using adjusted net earnings divided by diluted shares outstanding.

Sysco Corporation and its Consolidated Subsidiaries

Non-GAAP Reconciliation (Unaudited)

Impact of Certain Items

(Dollars in Thousands, Except for Share and Per Share Data)

  13-Week
Period Ended
Mar. 27, 2021
  13-Week
Period Ended
Mar. 28, 2020
  Change in
Dollars
  % Change
Operating expenses (GAAP) $ 1,886,751     $ 2,503,966     $ (617,215 )   -24.6   %
Impact of restructuring and transformational project costs (1) (34,953 )   (77,195 )   42,242     -54.7    
Impact of acquisition-related intangible amortization (2) (18,834 )   (17,321 )   (1,513 )   8.7    
Impact of bad debt reserve adjustments (3) 33,473     (153,499 )   186,972     -121.8    
Impact of goodwill impairment     (68,725 )   68,725     NM
Operating expenses adjusted for Certain Items (Non-GAAP) 1,866,437     2,187,226     (320,789 )   -14.7   %
Impact of currency fluctuations (4) (29,659 )       (29,659 )   -1.3    
Comparable operating expenses adjusted for Certain Items
using a constant currency basis (Non-GAAP)
$ 1,836,778     $ 2,187,226     $ (350,448 )   -16.0   %
               
Operating income (GAAP) $ 235,917     $ 60,274     $ 175,643     291.4   %
Impact of restructuring and transformational project costs (1) 34,953     77,195     (42,242 )   -54.7    
Impact of acquisition-related intangible amortization (2) 18,834     17,321     1,513     8.7    
Impact of bad debt reserve adjustments (3) (33,473 )   153,499     (186,972 )   -121.8    
Impact of goodwill impairment     68,725     (68,725 )   NM
Operating income adjusted for Certain Items (Non-GAAP) 256,231     377,014     (120,783 )   -32.0   %
Impact of currency fluctuations (4) 8,029         8,029     -2.1    
Comparable operating income adjusted for Certain Items
using a constant currency basis (Non-GAAP)
$ 264,260     $ 377,014     $ (112,754 )   -29.9   %
               
Other (income) expense (GAAP) $ (12,708 )   $ 5,200     $ (17,908 )   NM
Impact of loss on sale of businesses (10,790 )       (10,790 )   NM
Other (income) expense (Non-GAAP) $ (23,498 )   $ 5,200     $ (28,698 )   NM
               
Net earnings (loss) (GAAP) $ 88,927     $ (3,297 )   $ 92,224     NM
Impact of restructuring and transformational project costs (1) 34,953     77,195     (42,242 )   -54.7    
Impact of acquisition-related intangible amortization (2) 18,834     17,321     1,513     8.7    
Impact of bad debt reserve adjustments (3) (33,473 )   153,499     (186,972 )   -121.8    
Impact of goodwill impairment     68,725     (68,725 )   NM
Impact of loss on sale of businesses 10,790         10,790     NM
Tax impact of restructuring and transformational project costs (4) (10,300 )   (28,461 )   18,161     -63.8    
Tax impact of acquisition-related intangible amortization (4) (5,573 )   (6,777 )   1,204     -17.8    
Tax impact of bad debt reserve adjustments (4) 10,354     (46,410 )   56,764     -122.3    
Tax impact of loss on sale of businesses 301         301     NM
Net earnings adjusted for Certain Items (Non-GAAP) $ 114,813     $ 231,795     $ (116,982 )   -50.5   %
               
Diluted earnings (loss) per share (GAAP) $ 0.17     $ (0.01 )   $ 0.18     NM
Impact of restructuring and transformational project costs (1) 0.07     0.15     (0.08 )   -53.3    
Impact of acquisition-related intangible amortization (2) 0.04     0.03     0.01     33.3    
Impact of bad debt reserve adjustments (3) (0.07 )   0.30     (0.37 )   -123.3    
Impact of goodwill impairment     0.13     (0.13 )   NM
Impact of loss on sale of businesses 0.02         0.02     NM
Tax impact of restructuring and transformational project costs (4) (0.02 )   (0.06 )   0.04     -66.7    
Tax impact of acquisition-related intangible amortization (4) (0.01 )   (0.01 )       0.0    
Tax impact of bad debt reserve adjustments (4) 0.02     (0.09 )   0.11     -122.2    
Diluted EPS adjusted for Certain Items (Non-GAAP)

(5)
$ 0.22     $ 0.45     $ (0.23 )   -51.1   %
               
Diluted shares outstanding 514,585,129   512,657,657        

(1) Fiscal 2021 includes $21 million related to restructuring charges and $14 million related to various transformation initiative costs, primarily consisting of changes to our business technology strategy. Fiscal 2020 includes $48 million related to restructuring, facility closure and severance charges and $30 million related to various transformation initiative costs, primarily consisting of changes to our business technology strategy.
(2) Represents intangible amortization expense from the Brakes Acquisition, which is included in the results of International Foodservice.
(3) Fiscal 2021 represents the reduction of bad debt charges previously taken on pre-pandemic trade receivable balances in fiscal 2020. Fiscal 2020 represents excess bad debt charges recognized on the increase in past due receivables arising from the COVID-19 pandemic.
(4) Represents a constant currency adjustment, which eliminates the impact of foreign currency fluctuations on current year results.
(5) The tax impact of adjustments for Certain Items are calculated by multiplying the pretax impact of each Certain Item by the statutory rates in effect for each jurisdiction where the Certain Item was incurred.
(6) Individual components of diluted earnings per share may not add up to the total presented due to rounding. Total diluted earnings per share is calculated using adjusted net earnings divided by diluted shares outstanding.
  NM represents that the percentage change is not meaningful.



Sysco Corporation and its Consolidated Subsidiaries

Non-GAAP Reconciliation (Unaudited)

Impact of Certain Items

(Dollars in Thousands, Except for Share and Per Share Data)

  39-Week
Period Ended
Mar. 27, 2021
  39-Week
Period Ended
Mar. 28, 2020
  Change in
Dollars
  % Change
Operating expenses (GAAP) $ 5,573,413     $ 7,054,924     $ (1,481,511 )   -21.0   %
Impact of restructuring and transformational project costs (1) (95,078 )   (191,022 )   95,944     -50.2    
Impact of acquisition-related intangible amortization (2) (54,714 )   (51,543 )   (3,171 )   6.2    
Impact of bad debt reserve adjustments (3) 162,372     (153,499 )   315,871     -205.8    
Impact of goodwill impairment     (68,725 )   68,725     NM
Operating expenses adjusted for Certain Items (Non-GAAP) $ 5,585,993     $ 6,590,135     $ (1,004,142 )   -15.2   %
               
Operating income (GAAP) $ 867,558     $ 1,281,085     $ (413,527 )   -32.3   %
Impact of restructuring and transformational project costs (1) 95,078     191,022     (95,944 )   -50.2    
Impact of acquisition-related intangible amortization (2) 54,714     51,543     3,171     6.2    
Impact of bad debt reserve adjustments (3) (162,372 )   153,499     (315,871 )   -205.8    
Impact of goodwill impairment     68,725     (68,725 )   NM
Operating income adjusted for Certain Items (Non-GAAP) $ 854,978     $ 1,745,874     $ (890,896 )   -51.0   %
               
Other (income) expense (GAAP) $ (14,140 )   $ 7,505     $ (21,645 )   -288.4   %
Impact of loss on sale of businesses (22,834 )       (22,834 )   NM
Other (income) expense (Non-GAAP) $ (36,974 )   $ 7,505     $ (44,479 )   NM
               
Net earnings (loss) (GAAP) $ 373,116     $ 833,894     $ (460,778 )   -55.3   %
Impact of restructuring and transformational project costs (1) 95,078     191,022     (95,944 )   -50.2    
Impact of acquisition-related intangible amortization (2) 54,714     51,543     3,171     6.2    
Impact of bad debt reserve adjustments (3) (162,372 )   153,499     (315,871 )   -205.8    
Impact of goodwill impairment     68,725     (68,725 )   NM
Impact of loss on sale of businesses 22,834         22,834     NM
Tax impact of restructuring and transformational project costs (4) (26,886 )   (57,756 )   30,870     -53.4    
Tax impact of acquisition-related intangible amortization (4) (15,471 )   (15,584 )   113     -0.7    
Tax impact of bad debt reserve adjustments (4) 45,913     (46,410 )   92,323     -198.9    
Tax impact of loss on sale of businesses (7,251 )       (7,251 )   NM
Impact of foreign tax rate change (5,548 )   924     (6,472 )   NM
Net earnings adjusted for Certain Items (Non-GAAP) $ 374,127     $ 1,179,857     $ (805,730 )   -68.3   %
               
Diluted earnings (loss) per share (GAAP) $ 0.73     $ 1.62     $ (0.89 )   -54.9   %
Impact of restructuring and transformational project costs (1) 0.19     0.37     (0.18 )   -48.6    
Impact of acquisition-related intangible amortization (2) 0.11     0.10     0.01     10.0    
Impact of bad debt reserve adjustments (3) (0.32 )   0.30     (0.62 )   -206.7    
Impact of goodwill impairment     0.13     (0.13 )   NM
Impact of loss on sale of businesses 0.04         0.04     NM
Tax impact of restructuring and transformational project costs (4) (0.05 )   (0.11 )   0.06     -54.5    
Tax impact of acquisition-related intangible amortization (4) (0.03 )   (0.03 )       0.0    
Tax impact of bad debt reserve adjustments (4) 0.09     (0.09 )   0.18     -200.0    
Tax impact of loss on sale of businesses (0.01 )       (0.01 )   NM
Tax impact of foreign tax rate change (0.01 )       (0.01 )   NM
Diluted EPS adjusted for Certain Items (Non-GAAP)

(5)
$ 0.73     $ 2.29     $ (1.56 )   -68.1   %
               
Diluted shares outstanding 512,688,895     515,632,815          

(1) Fiscal 2021 includes $56 million related to restructuring, severance and facility closure charges, and $39 million related to various transformation initiative costs, primarily consisting of changes to our business technology strategy. Fiscal 2020 includes $100 million related to restructuring, severance, and facility closure charges and $91 million related to various transformation initiative costs, primarily consisting of changes to our business technology strategy.
(2) Represents intangible amortization expense from the Brakes Acquisition, which is included in the results of International Foodservice.
(3) Fiscal 2021 represents the reduction of bad debt charges previously taken on pre-pandemic trade receivable balances in fiscal 2020. Fiscal 2020 represents excess bad debt charges recognized on the increase in past due receivables arising from the COVID-19 pandemic.
(4) The tax impact of adjustments for Certain Items are calculated by multiplying the pretax impact of each Certain Item by the statutory rates in effect for each jurisdiction where the Certain Item was incurred.
(5) Individual components of diluted earnings per share may not add up to the total presented due to rounding. Total diluted earnings per share is calculated using adjusted net earnings divided by diluted shares outstanding.
  NM represents that the percentage change is not meaningful.



Sysco Corporation and its Consolidated Subsidiaries

Segment Results

Non-GAAP Reconciliation (Unaudited)

Impact of Certain Items on Applicable Segments

(Dollars in Thousands)

  13-Week
Period Ended
Mar. 27, 2021
  13-Week
Period Ended
Mar. 28, 2020
  Change in
Dollars
  %/bps
Change
U.S. FOODSERVICE OPERATIONS              
Sales $ 8,360,241       $ 9,587,005       $ (1,226,764 )   -12.8 %
Gross Profit 1,634,837       1,895,378       (260,541 )   -13.7 %
Gross Margin 19.6   %   19.8   %       -22 bps
               
Operating expenses (GAAP) $ 1,089,335       $ 1,431,205       $ (341,870 )   -23.9 %
Impact of restructuring and transformational project costs (1) (1,285 )     (1,403 )     118     -8.4  
Impact of bad debt reserve adjustments (2) 21,669       (107,230 )     128,899     -120.2  
Operating expenses adjusted for Certain Items (Non-GAAP) $ 1,109,719       $ 1,322,572       $ (212,853 )   -16.1 %
               
Operating income (GAAP) $ 545,502       $ 464,173       $ 81,329     17.5 %
Impact of restructuring and transformational project costs (1) 1,285       1,403       (118 )   -8.4  
Impact of bad debt reserve adjustments (2) (21,669 )     107,230       (128,899 )   -120.2  
Operating income adjusted for Certain Items (Non-GAAP) $ 525,118       $ 572,806       $ (47,688 )   -8.3 %
               
INTERNATIONAL FOODSERVICE OPERATIONS              
Sales (GAAP) $ 1,723,126       $ 2,508,642       $ (785,516 )   -31.3 %
Impact of currency fluctuations (3) (103,338 )           (103,338 )   4.1  
Comparable sales using a constant currency basis (Non-GAAP) $ 1,619,788       $ 2,508,642       $ (888,854 )   -35.4 %
               
Gross Profit (GAAP) $ 325,200       $ 500,929       $ (175,729 )   -35.1 %
Impact of currency fluctuations (3) (20,660 )           (20,660 )   4.1  
Comparable gross profit using a constant currency basis (Non-GAAP) $ 304,540       $ 500,929       $ (196,389 )   -39.2 %
               
Gross Margin (GAAP) 18.9   %   20.0   %       -110 bps
Impact of currency fluctuations (3) 0.1                 7 bps
Comparable gross margin using a constant currency basis (Non-GAAP) 18.8   %   20.0   %       -117 bps
               
Operating expenses (GAAP) $ 446,687       $ 584,715       $ (138,028 )   -23.6 %
Impact of restructuring and transformational project costs (4) (18,635 )     (25,180 )     6,545     -26.0  
Impact of acquisition-related intangible amortization (5) (18,834 )     (17,321 )     (1,513 )   8.7  
Impact of bad debt reserve adjustments (2) 8,357       (46,269 )     54,626     -118.1  
Operating expenses adjusted for Certain Items (Non-GAAP) $ 417,575       $ 495,945       $ (78,370 )   -15.8 %
Impact of currency fluctuations (3) (28,811 )           (28,811 )   5.8  
Comparable operating expenses adjusted for Certain
Items using a constant currency basis (Non-GAAP)
$ 388,764       $ 495,945       $ (107,181 )   -21.6 %
               
Operating (loss) income (GAAP) $ (121,487 )     $ (83,786 )     $ (37,701 )   -45.0 %
Impact of restructuring and transformational project costs (4) 18,635       25,180       (6,545 )   -26.0  
Impact of acquisition-related intangible amortization (5) 18,834       17,321       1,513     8.7  
Impact of bad debt reserve adjustments (2) (8,357 )     46,269       (54,626 )   -118.1  
Operating (loss) income adjusted for Certain Items (Non-GAAP) $ (92,375 )     $ 4,984       $ (97,359 )   NM
Impact of currency fluctuations (3) 8,151             8,151     NM
Comparable operating (loss) income adjusted for Certain
Items using a constant currency basis (Non-GAAP)
$ (84,224 )     $ 4,984       $ (89,208 )   NM
               
SYGMA              
Sales $ 1,580,695       $ 1,364,111       $ 216,584     15.9 %
Gross Profit 133,478       118,891       14,587     12.3 %
Gross Margin 8.4   %   8.7   %       -27 bps
               
Operating expenses (GAAP) $ 120,541       $ 108,590       $ 11,951     11.0 %
Impact of restructuring and transformational project costs (1)       (122 )     122     NM
Operating expenses adjusted for Certain Items (Non-GAAP) $ 120,541       $ 108,468       $ 12,073     11.1 %
               
Operating income (GAAP) $ 12,937       $ 10,301       $ 2,636     25.6 %
Impact of restructuring and transformational project costs (1)       122       (122 )   NM
Operating (loss) income adjusted for Certain Items (Non-GAAP) $ 12,937       $ 10,423       $ 2,514     24.1 %
               
OTHER              
Sales $ 160,527       $ 238,941       $ (78,414 )   -32.8 %
Gross Profit 37,911       56,000       (18,089 )   -32.3 %
Gross Margin 23.6   %   23.4   %       18 bps
               
Operating expenses (GAAP) $ 32,027       $ 75,051       $ (43,024 )   -57.3 %
Impact of bad debt reserve adjustments (2) 3,447             3,447     NM
Impact of goodwill impairment       (11,660 )     11,660     NM
Operating expenses adjusted for Certain Items (Non-GAAP) $ 35,474       $ 63,391       (27,917 )   -44.0 %
               
Operating (loss) income (GAAP) $ 5,884       $ (19,051 )     $ 24,935     130.9 %
Impact of bad debt reserve adjustments (2) (3,447 )           (3,447 )   NM
Impact of goodwill impairment       11,660       (11,660 )   NM
Operating (loss) income adjusted for Certain Items (Non-GAAP) $ 2,437       $ (7,391 )     9,828     133.0 %
               
CORPORATE              
Gross Profit $ (8,758 )     $ (6,958 )     $ (1,800 )   -25.9 %
               
Operating expenses (GAAP) $ 198,161       $ 304,405       $ (106,244 )   -34.9 %
Impact of restructuring and transformational project costs (6) (15,033 )     (50,490 )     35,457     -70.2  
Impact of goodwill impairment       (57,065 )     57,065     NM
Operating expenses adjusted for Certain Items (Non-GAAP) $ 183,128       $ 196,850       $ (13,722 )   -7.0 %
               
Operating loss (GAAP) $ (206,919 )     $ (311,363 )     $ 104,444     33.5 %
Impact of restructuring and transformational project costs (6) 15,033       50,490       (35,457 )   -70.2  
Impact of goodwill impairment       57,065       (57,065 )   NM
Operating loss adjusted for Certain Items (Non-GAAP) $ (191,886 )     $ (203,808 )     $ 11,922     5.8 %
               
TOTAL SYSCO              
Sales $ 11,824,589       $ 13,698,699       $ (1,874,110 )   -13.7 %
Gross Profit 2,122,668       2,564,240       (441,572 )   -17.2 %
Gross Margin 18.0   %   18.7   %       -77 bps
               
Operating expenses (GAAP) $ 1,886,751       $ 2,503,966       $ (617,215 )   -24.6 %
Impact of restructuring and transformational project costs (1) (4) (6) (34,953 )     (77,195 )     42,242     -54.7  
Impact of acquisition-related intangible amortization (5) (18,834 )     (17,321 )     (1,513 )   8.7  
Impact of bad debt reserve adjustments (2) 33,473       (153,499 )     186,972     -121.8  
Impact of goodwill impairment       (68,725 )     68,725     NM
Operating expenses adjusted for Certain Items (Non-GAAP) $ 1,866,437       $ 2,187,226       $ (320,789 )   -14.7 %
               
Operating income (GAAP) $ 235,917       $ 60,274       $ 175,643     291.4 %
Impact of restructuring and transformational project costs (1) (4) (6) 34,953       77,195       (42,242 )   -54.7  
Impact of acquisition-related intangible amortization (5) 18,834       17,321       1,513     8.7  
Impact of bad debt reserve adjustments (2) (33,473 )     153,499       (186,972 )   -121.8  
Impact of goodwill impairment       68,725       (68,725 )   NM
Operating income adjusted for Certain Items (Non-GAAP) $ 256,231       $ 377,014       $ (120,783 )   -32.0 %

(1) Includes charges related to restructuring and business transformation projects.
(2) Fiscal 2021 represents the reduction of bad debt charges previously taken on pre-pandemic trade receivable balances in fiscal 2020. Fiscal 2020 represents excess bad debt charges recognized on the increase in past due receivables arising from the COVID-19 pandemic.
(3) Represents a constant currency adjustment, which eliminates the impact of foreign currency fluctuations on current year results.
(4) Includes restructuring, severance and facility closure costs primarily in Europe.
(5) Represents intangible amortization expense from the Brakes Acquisition.
(6) Includes various transformation initiative costs, primarily consisting of changes to our business technology strategy.
  NM represents that the percentage change is not meaningful.



Sysco Corporation and its Consolidated Subsidiaries

Segment Results

Non-GAAP Reconciliation (Unaudited)

Impact of Certain Items on Applicable Segments

(Dollars in Thousands)

  39-Week
Period Ended
Mar. 27, 2021
  39-Week
Period Ended
Mar. 28, 2020
  Change in
Dollars
  %/bps
Change
U.S. FOODSERVICE OPERATIONS              
Sales $ 24,205,917       $ 30,659,215       $ (6,453,298 )   -21.0   %
Gross Profit 4,793,866       6,089,171       (1,295,305 )   -21.3   %
Gross Margin 19.8   %   19.9   %       -6 bps
               
Operating expenses (GAAP) $ 3,174,704       $ 4,126,576       $ (951,872 )   -23.1   %
Impact of restructuring and transformational project costs (1) (4,010 )     (9,208 )     5,198     -56.5    
Impact of bad debt reserve adjustments (2) 123,225       (107,230 )     230,455     -214.9    
Operating expenses adjusted for Certain Items (Non-GAAP) $ 3,293,919       $ 4,010,138       $ (716,219 )   -17.9   %
               
Operating income (GAAP) $ 1,619,162       $ 1,962,595       $ (343,433 )   -17.5   %
Impact of restructuring and transformational project costs (1) 4,010       9,208       (5,198 )   -56.5    
Impact of bad debt reserve adjustments (2) (123,225 )     107,230       (230,455 )   -214.9    
Operating income adjusted for Certain Items (Non-GAAP) $ 1,499,947       $ 2,079,033       $ (579,086 )   -27.9   %
               
INTERNATIONAL FOODSERVICE OPERATIONS              
Sales (GAAP) $ 5,854,608       $ 8,311,081       $ (2,456,473 )   -29.6   %
Impact of currency fluctuations (3) (197,380 )           (197,380 )   2.4    
Comparable sales using a constant currency basis (Non-GAAP) $ 5,657,228       $ 8,311,081       $ (2,653,853 )   -31.9   %
               
Gross Profit (GAAP) $ 1,149,438       $ 1,692,153       $ (542,715 )   -32.1   %
Impact of currency fluctuations (3) (43,631 )           (43,631 )   2.6    
Comparable gross profit using a constant currency basis (Non-GAAP) $ 1,105,807       $ 1,692,153       $ (586,346 )   -34.7   %
               
Gross Margin (GAAP) 19.6   %   20.4   %       -73 bps
Impact of currency fluctuations (3) 0.1                 9 bps
Comparable gross margin using a constant currency basis (Non-GAAP) 19.5   %   20.4   %       -81 bps
               
Operating expenses (GAAP) $ 1,351,411       $ 1,686,258       $ (334,847 )   -19.9   %
Impact of restructuring and transformational project costs (4) (52,033 )     (74,302 )     22,269     -30.0    
Impact of acquisition-related intangible amortization (5) (54,714 )     (51,543 )     (3,171 )   6.2    
Impact of bad debt reserve adjustments (2) 33,583       (46,269 )     79,852     -172.6    
Operating expenses adjusted for Certain Items (Non-GAAP) $ 1,278,247       $ 1,514,144       $ (235,897 )   -15.6   %
Impact of currency fluctuations (3) (56,263 )           (56,263 )   3.7    
Comparable operating expenses adjusted for Certain
Items using a constant currency basis (Non-GAAP)
$ 1,221,984       $ 1,514,144       $ (292,160 )   -19.3   %
               
Operating (loss) income (GAAP) $ (201,973 )     $ 5,895       $ (207,868 )   NM
Impact of restructuring and transformational project costs (4) 52,033       74,302       (22,269 )   -30.0    
Impact of acquisition-related intangible amortization (5) 54,714       51,543       3,171     6.2    
Impact of bad debt reserve adjustments (2) (33,583 )     46,269       (79,852 )   -172.6    
Operating (loss) income adjusted for Certain Items (Non-GAAP) $ (128,809 )     $ 178,009       $ (306,818 )   -172.4   %
Impact of currency fluctuations (3) 12,632             12,632     -7.1    
Comparable operating (loss) income adjusted for Certain
Items using a constant currency basis (Non-GAAP)
$ (116,177 )     $ 178,009       $ (294,186 )   -165.3   %
               
SYGMA              
Sales $ 4,625,244       $ 4,266,998       $ 358,246     8.4   %
Gross Profit 394,318       369,048       25,270     6.8   %
Gross Margin 8.5   %   8.6   %       -12 bps
               
Operating expenses (GAAP) $ 358,361       $ 341,316       $ 17,045     5.0   %
Impact of restructuring and transformational project costs (1) (7 )     (3,662 )     3,655     -99.8    
Operating expenses adjusted for Certain Items (Non-GAAP) $ 358,354       $ 337,654       $ 20,700     6.1   %
               
Operating income (GAAP) $ 35,957       $ 27,732       $ 8,225     29.7   %
Impact of restructuring and transformational project costs (1) 7       3,662       (3,655 )   -99.8    
Operating (loss) income adjusted for Certain Items (Non-GAAP) $ 35,964       $ 31,394       $ 4,570     14.6   %
               
OTHER              
Sales $ 475,181       $ 789,452       $ (314,271 )   -39.8   %
Gross Profit 114,108       194,248       (80,140 )   -41.3   %
Gross Margin 24.0   %   24.6   %       -59 bps
               
Operating expenses (GAAP) $ 109,247       $ 193,762       $ (84,515 )   -43.6   %
Impact of bad debt reserve adjustments (2) 5,564             5,564     NM
Impact of goodwill impairment       (11,660 )     11,660     NM
Operating expenses adjusted for Certain Items (Non-GAAP) $ 114,811       $ 182,102       $ (67,291 )   -37.0   %
               
Operating (loss) income (GAAP) $ 4,861       $ 486       $ 4,375     NM
Impact of bad debt reserve adjustments (2) (5,564 )           (5,564 )   NM
Impact of goodwill impairment       11,660       (11,660 )   NM
Operating (loss) income adjusted for Certain Items (Non-GAAP) $ (703 )     $ 12,146       (12,849 )   -105.8   %
               
CORPORATE              
Gross Profit $ (10,759 )     $ (8,611 )     $ (2,148 )   -24.9   %
               
Operating expenses (GAAP) $ 579,690       $ 707,012       $ (127,322 )   -18.0   %
Impact of restructuring and transformational project costs (6) (39,028 )     (103,850 )     64,822     -62.4    
Impact of goodwill impairment       (57,065 )     57,065     NM
Operating expenses adjusted for Certain Items (Non-GAAP) $ 540,662       $ 546,097       $ (5,435 )   -1.0   %
               
Operating loss (GAAP) $ (590,449 )     $ (715,623 )     $ 125,174     17.5   %
Impact of restructuring and transformational project costs (6) 39,028       103,850       (64,822 )   -62.4    
Impact of goodwill impairment       57,065       (57,065 )   NM
Operating loss adjusted for Certain Items (Non-GAAP) $ (551,421 )     $ (554,708 )     $ 3,287     0.6   %
               
TOTAL SYSCO              
Sales $ 35,160,950       $ 44,026,746       $ (8,865,796 )   -20.1   %
Gross Profit 6,440,971       8,336,009       (1,895,038 )   -22.7   %
Gross Margin 18.3   %   18.9   %       -62 bps
               
Operating expenses (GAAP) $ 5,573,413       $ 7,054,924       $ (1,481,511 )   -21.0   %
Impact of restructuring and transformational project costs (1) (4) (6) (95,078 )     (191,022 )     95,944     -50.2    
Impact of acquisition-related intangible amortization (5) (54,714 )     (51,543 )     (3,171 )   6.2    
Impact of bad debt reserve adjustments (2) 162,372       (153,499 )     315,871     -205.8    
Impact of goodwill impairment       (68,725 )     68,725     NM
Operating expenses adjusted for Certain Items (Non-GAAP) $ 5,585,993       $ 6,590,135       $ (1,004,142 )   -15.2   %
               
Operating income (GAAP) $ 867,558       $ 1,281,085       $ (413,527 )   -32.3   %
Impact of restructuring and transformational project costs (1) (4) (6) 95,078       191,022       (95,944 )   -50.2    
Impact of acquisition-related intangible amortization (5) 54,714       51,543       3,171     6.2    
Impact of bad debt reserve adjustments (2) (162,372 )     153,499       (315,871 )   -205.8    
Impact of goodwill impairment       68,725       (68,725 )   NM
Operating income adjusted for Certain Items (Non-GAAP) $ 854,978       $ 1,745,874       $ (890,896 )   -51.0   %

(1) Includes charges related to restructuring and business transformation projects.
(2) Fiscal 2021 represents the reduction of bad debt charges previously taken on pre-pandemic trade receivable balances in fiscal 2020. Fiscal 2020 represents excess bad debt charges recognized on the increase in past due receivables arising from the COVID-19 pandemic.
(3) Represents a constant currency adjustment, which eliminates the impact of foreign currency fluctuations on current year results.
(4) Includes restructuring, severance and facility closure costs primarily in Europe.
(5) Represents intangible amortization expense from the Brakes Acquisition.
(6) Includes various transformation initiative costs, primarily consisting of changes to our business technology strategy.
  NM represents that the percentage change is not meaningful.



Sysco Corporation and its Consolidated Subsidiaries

Non-GAAP Reconciliation (Unaudited)

Free Cash Flow

(In Thousands)

Free cash flow represents net cash provided from operating activities less purchases of plant and equipment and includes proceeds from sales of plant and equipment. Sysco considers free cash flow to be a liquidity measure that provides useful information to management and investors about the amount of cash generated by the business after the purchases and sales of buildings, fleet, equipment and technology, which may potentially be used to pay for, among other things, strategic uses of cash including dividend payments, share repurchases and acquisitions. However, free cash flow may not be available for discretionary expenditures, as it may be necessary that we use it to make mandatory debt service or other payments. Free cash flow should not be used as a substitute for the most comparable GAAP measure in assessing the company’s liquidity for the periods presented. An analysis of any non-GAAP financial measure should be used in conjunction with results presented in accordance with GAAP. In the table that follows, free cash flow for each period presented is reconciled to net cash provided by operating activities.

  39-Week
Period Ended
Mar. 27, 2021
  39-Week
Period Ended
Mar. 28, 2020
  39-Week
Period Change
in Dollars
Net cash provided by operating activities (GAAP) $ 1,479,784     $ 1,078,469     $ 401,315  
Additions to plant and equipment (251,167 )   (603,865 )   352,698  
Proceeds from sales of plant and equipment 19,308     13,245     6,063  
Free Cash Flow (Non-GAAP) $ 1,247,925     $ 487,849     $ 760,076  



Sysco Corporation and its Consolidated Subsidiaries

Non-GAAP Reconciliation (Unaudited)

Impact of Certain Items on Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA)

(Dollars in Thousands)

EBITDA represents net earnings (loss) plus (i) interest expense, (ii) income tax expense and benefit, (iii) depreciation and (iv) amortization. The net earnings (loss) component of our EBITDA calculation is impacted by Certain Items that we do not consider representative of our underlying performance. As a result, in the non-GAAP reconciliations below for each period presented, adjusted EBITDA is computed as EBITDA plus the impact of Certain Items, excluding Certain items related to interest expense, income taxes, depreciation and amortization. Sysco’s management considers growth in this metric to be a measure of overall financial performance that provides useful information to management and investors about the profitability of the business, as it facilitates comparison of performance on a consistent basis from period to period by providing a measurement of recurring factors and trends affecting our business. Additionally, it is a commonly used component metric used to inform on capital structure decisions. Adjusted EBITDA should not be used as a substitute for the most comparable GAAP measure in assessing the company’s financial performance for the periods presented. An analysis of any non-GAAP financial measure should be used in conjunction with results presented in accordance with GAAP. In the tables that follow, adjusted EBITDA for each period presented is reconciled to net earnings (loss).

  13-Week
Period Ended
Mar. 27, 2021
  13-Week
Period Ended
Mar. 28, 2020
  Change in
Dollars
  % Change
Net earnings (loss) (GAAP) $ 88,927     $ (3,297 )   $ 92,224     NM
Interest (GAAP) 145,773     83,854     61,919     73.8    
Income taxes (GAAP) 13,925     (25,483 )   39,408     -154.6    
Depreciation and amortization (GAAP) 177,139     186,172     (9,033 )   -4.9    
EBITDA (Non-GAAP) $ 425,764     $ 241,246     $ 184,518     76.5   %
Certain Item adjustments:              
Impact of restructuring and transformational project costs (1) $ 34,301     $ 74,656     $ (40,355 )   -54.1   %
Impact of bad debt reserve adjustments (2) (33,473 )   153,499     (186,972 )   -121.8    
Impact of goodwill impairment     68,725     (68,725 )   NM
Impact of loss on sale of businesses 10,790         10,790     NM
EBITDA adjusted for Certain Items (Non-GAAP) $ 437,382     $ 538,126     $ (100,744 )   -18.7   %

(1) Includes various transformation initiative costs, primarily consisting of changes to our business technology strategy, excluding charges related to accelerated depreciation.
(2) Fiscal 2021 represents the reduction of bad debt charges previously taken on pre-pandemic trade receivable balances in fiscal 2020. Fiscal 2020 represents excess bad debt charges recognized on the increase in past due receivables arising from the COVID-19 pandemic.

  39-Week
Period Ended
Mar. 27, 2021
  39-Week
Period Ended
Mar. 28, 2020
  Change in
Dollars
  % Change
Net earnings (loss) (GAAP) $ 373,116     $ 833,894     $ (460,778 )   -55.3   %
Interest (GAAP) 438,988     243,951     195,037     79.9    
Income taxes (GAAP) 69,594     195,735     (126,141 )   -64.4    
Depreciation and amortization (GAAP) 542,471     558,588     (16,117 )   -2.9    
EBITDA (Non-GAAP) $ 1,424,169     $ 1,832,168     $ (407,999 )   -22.3   %
Certain Item adjustments:              
Impact of restructuring and transformational project costs (1) $ 89,253     $ 174,066     $ (84,813 )   -48.7   %
Impact of bad debt reserve adjustments (2) (162,372 )   153,499     (315,871 )   -205.8    
Impact of goodwill impairment     68,725     (68,725 )   NM
Impact of loss on sale of businesses 22,834         22,834     NM
EBITDA adjusted for Certain Items (Non-GAAP) $ 1,373,884     $ 2,228,458     $ (854,574 )   -38.3   %

(1) Includes various transformation initiative costs, primarily consisting of changes to our business technology strategy, excluding charges related to accelerated depreciation.
(2) Fiscal 2021 represents the reduction of bad debt charges previously taken on pre-pandemic trade receivable balances in fiscal 2020. Fiscal 2020 represents excess bad debt charges recognized on the increase in past due receivables arising from the COVID-19 pandemic.

  13-Week Period Ended 39-Week
Period Ended
  Sep. 26, 2020   Dec. 26, 2020   Mar. 27, 2021   Mar. 27, 2021
Net earnings (loss) (GAAP) $ 216,900     $ 67,289     $ 88,927     $ 373,116  
Interest (GAAP) 146,717     146,498     145,773     438,988  
Income taxes (GAAP) 41,838     13,831     13,925     69,594  
Depreciation and amortization (GAAP) 180,521     184,811     177,139     542,471  
EBITDA (Non-GAAP) $ 585,976     $ 412,429     $ 425,764     $ 1,424,169  
Certain Item adjustments:              
Impact of restructuring and transformational project costs (1) $ 25,278     $ 29,674     $ 34,301     $ 89,253  
Impact of bad debt reserve adjustments (2) (98,628 )   (30,271 )   (33,473 )   (162,372 )
Impact of loss on sale of businesses 12,044         10,790     22,834  
EBITDA adjusted for certain items (Non-GAAP) $ 524,670     $ 411,832     $ 437,382     $ 1,373,884  

(1) Includes various transformation initiative costs, primarily consisting of changes to our business technology strategy, excluding charges related to accelerated depreciation.
(2) Fiscal 2021 represents the reduction of bad debt charges previously taken on pre-pandemic trade receivable balances in fiscal 2020.

  13-Week Period Ended   52-Week
Period Ended
  Sep. 28, 2019   Dec. 28, 2019   Mar. 28, 2020   June 27, 2020   June 27, 2020
Net earnings (loss) (GAAP) $ 453,781     $ 383,410     $ (3,297 )     $ (618,419 )     $ 215,475  
Interest (GAAP) 83,335     76,762     83,854       164,269       408,220  
Income taxes (GAAP) 128,090     93,128     (25,483 )     (117,826 )     77,909  
Depreciation and amortization (GAAP) 187,405     185,011     186,172       247,177       805,765  
EBITDA (Non-GAAP) $ 852,611     $ 738,311     $ 241,246       $ (324,799 )     $ 1,507,369  
Certain Item adjustments :                  
Impact of restructuring and transformational project costs (1) $ 45,546     $ 53,864     $ 74,656       $ 116,218       $ 290,284  
Impact of bad debt reserve adjustments (2)         153,499       169,903       323,402  
Impact of goodwill impairment         68,725       134,481       203,206  
Impact of loss on assets held for sale               46,968       46,968  
EBITDA adjusted for certain items (Non-GAAP) $ 898,157     $ 792,175     $ 538,126       $ 142,771       $ 2,371,229  

(1) Includes various transformation initiative costs, primarily consisting of changes to our business technology strategy, excluding charges related to accelerated depreciation.
(2) Fiscal 2020 represents excess bad debt charges recognized on the increase in past due receivables arising from the COVID-19 pandemic.

For more information contact:
   
Shannon Mutschler
Media Contact
[email protected]
T 281-584-5980
Rachel Lee
Investor Contact
[email protected]
T 281-436-7815



Great Lakes Reports First Quarter Results


First quarter net income of $8.8 million


First quarter adjusted EBITDA of $26.8 million


First quarter awards of $90.3 million resulting in 42% bid market share

HOUSTON, May 04, 2021 (GLOBE NEWSWIRE) — Great Lakes Dredge & Dock Corporation (Nasdaq:GLDD), the largest provider of dredging services in the United States, today reported financial results for the quarter ended March 31, 2021.


First Quarter 2021 Highlights

  • Revenue was $177.6 million in the first quarter
  • Total operating income was $16.6 million in the first quarter
  • Net income was $8.8 million in the first quarter
  • Adjusted EBITDA was $26.8 million in the first quarter


Management Commentary

Lasse Petterson, President and Chief Executive Officer commented, “During 2020 as the COVID-19 pandemic hit our nation, Great Lakes was able to adjust and navigate the difficulties and challenges the pandemic posed to our operations. However, as the 3rd wave of the pandemic spread through our population, we started to see significant additional direct costs and operational interruptions in the first quarter of 2021. Several of our vessel crews were infected despite our extensive testing and isolation protocols. Vessels were required to go to shore for crew changes and the vessels had to be disinfected before returning to work. This impacted the vessels’ scheduling and availability, which impacted our productivity on several projects and led to delays which pushed revenue from the first quarter into remaining quarters of 2021. Today the projects and vessels that were impacted are back in operation and with our solid backlog, vaccinations increasing, and stronger performance expectations in the third and fourth quarters, we do not see adjusting our full year expectations at this time. Approximately twenty three revenue days were lost due to COVID outbreaks. Downtime for the vessels impacted directly by COVID delays equated to $3.9 million of revenue and $1.2 million of gross margin. The direct COVID costs of at home and on site testing and costs of quarantining were $4.3 million in the quarter. We have initiated an extensive vaccination effort of our crews and staff and as of today we have approximately 20% of our staff either fully vaccinated or partially vaccinated. Our target is to have the majority of all staff and crew vaccinated in the second quarter of 2021, which we hope will greatly reduce or even potentially eliminate further impacts on our operations.

We ended the quarter with net income of $8.8 million and Adjusted EBITDA of $26.8 million compared to the first quarter of 2020 that ended with $34 million of net income and $61.4 million in Adjusted EBITDA. The first quarter of 2020 was a record breaking quarter for Great Lakes, driven by robust performance on several projects and no vessels in drydock, therefore comparison to this quarter was expected to be difficult.   In addition to the COVID related impacts, in the first quarter of 2021 we experienced some extended drydocks and equipment failure which impacted project schedules.

We expect the domestic bid market to be just as strong this year as it was in 2020. In the first quarter, Great Lakes announced awards for the Boston Phase 3 Deepening Project and the Panama City beach renourishment totaling $90.3 million. We also were the low bidder on the Mobile Deepening Phase 3 project that was pending award for $53.9 million at the end of the first quarter, but has since been awarded. In addition, in April of this year we were awarded the Golden Triangle Marsh Creation Project in Louisiana for $32.4 million and we were the low bidder on the Captiva Island Project for $15.6 million.

In the offshore wind market, the Biden administration has pushed to accelerate wind energy development and has set a target to install 30GW of offshore wind energy by 2030. This target confirms our plans and determination to evaluate future investments in the offshore wind market. In December of last year, we announced the design and development of the first U.S. flagged Jones Act compliant, inclined fall-pipe vessel for subsea rock installation for wind turbine foundations and in March we awarded the integration engineering and detail design package to Ulstein. This vessel would represent a significant critical advancement in building the U.S. logistics infrastructure to support the future of the new U.S. offshore wind industry. Delivery of the vessel is expected in late 2023.”


Quarterly Results

  • Revenue was $177.6 million, a decrease of $40.1 million from the first quarter of 2020. The lower revenue in the first quarter of 2021 was due to lower coastal protection and capital dredging revenue, offset by an increase in revenue from maintenance dredging projects. The decrease in revenue compared to the first quarter of 2020 is mainly attributed to the fact that in last year’s first quarter there were no vessels in drydock, which allowed for more revenue generation, and we also had exceptional performance on several projects.
  • Gross margin percentage declined to 18.6% in the first quarter of 2021 from 31.5% in the first quarter of 2020. Direct COVID-19 costs had an unfavorable impact of $4.3 million on gross profit during the first quarter and $1.2 million of opportunity lost related to the impacted vessels. In addition, productivity impacts and delays affected several projects. Also both the Dredge55 and the Carolina remained in drydock for the entire quarter but are expected to return to work in the second quarter of 2021.
  • Operating income was $16.6 million, which is a $36.4 million decrease from the prior year quarter. The decrease is a direct result of lower gross margin. General and administrative expenses was $0.7 million higher than prior year. The increase in general and administrative expenses for the quarter was due to higher relocation expense in current year related to regional office and headquarter partially offset by a decrease in incentive pay.
  • Net income for the quarter was $8.8 million compared to $34.0 million in the prior year quarter. The shortfall in operating income was offset partially by lower tax expense and interest expense.
  • At March 31, 2021, the Company had $177.6 million in cash and total debt of $324.0 million.
  • At March 31, 2021, the Company had $486.0 million in backlog, a decrease of $73.4 million from December 31, 2020. This decrease was expected as bidding activity is historically low in the first quarter of the year.
  • Capital expenditures for the first quarter of 2021 were $16.5 million, which includes $5.4 million for our new hopper dredge, $1.0 million for our rock installation vessel, and $1.4 million for our new multicats.


Market Update

At the end of 2020, the domestic bid market for the year had reached $1.8 billion in projects bid. We continue to be optimistic and believe the 2021 domestic market will remain strong. The bid market continues to be driven by the large-scale port deepening projects along the East and Gulf coasts. We expect that 2021 will see bids for multiple project phases for port deepenings in Corpus Christi, Norfolk and the Houston ship channel that will continue for the next several years. Strong hurricane and storm seasons have resulted in an increase in beach erosion and other damage which adds to the recurring nature of our business and the need for more frequent coastal protection and port maintenance projects. 2021 will also see several major coastal marsh creation projects in Louisiana. These projects are needed as they help to reduce the risk of future damage from flood and storm events and are important in providing resilience to protect coastal communities and ecosystems as well as driving job creation and economic development. We have seen support for the dredging industry in the U.S. Army Corps of Engineers’ 2021 budget that was approved at a record high of $7.3 billion. In addition, the 2020 Water Resource Development Act (the “WRDA”) was signed into law and included some additional reforms to the Harbor Maintenance Trust Fund (the “HMTF”). These reforms will allow Congress to, for the first time, drawdown from the $9.3 billion surplus in the HMTF. This is in addition to having the annual cap lifted on the HMTF earlier in the year in the Coronavirus Aid, Relief and Economic Security Act. WRDA also includes significant language encouraging more beneficial use of dredged material and natural infrastructure, both of which are important environmental issues.

As noted above, we see strong support for offshore wind from the Biden administration. In March, the White House announced new initiatives that will advance the administration’s goals to expand the nation’s offshore wind energy capacity in the coming decade by opening new areas of development, improving environmental permitting, and increasing public financing for projects. The administration committed to approving 16 offshore wind projects by 2025 and stated it would direct $230 million in federal transportation dollars to fund port infrastructure and earmark $3 billion in loan guarantees from the Department of Energy. President Biden has set a target to install 30GW of offshore wind energy by 2030. In addition, in January, the White House released a Buy America fact sheet that emphasized President Biden’s strong support for the Jones Act and its importance to renewable offshore energy.

Great Lakes remains committed to maintaining the health and safety of our team members through an Incident & Injury Free® (IIF®) safety management program. This value-based approach has allowed us to respond quickly and effectively to the COVID-19 pandemic and any challenges resulting from the pandemic, and has helped us to minimize the financial impact.

The Company will be holding a conference call at 9:00 a.m. C.D.T. today where we will further discuss these results. Information on this conference call can be found below.


Conference Call Information

The Company will conduct a quarterly conference call, which will be held on Tuesday, May 4, 2021 at 9:00 a.m. C.D.T (10:00 a.m. E.S.T.). The call in number is (877) 377-7553 and Conference ID is 8696297. The conference call will be available by replay until Thursday, May 6, 2021 by calling (855) 859-2056 and providing Conference ID 8696297. The live call and replay can also be heard on the Company’s website, www.gldd.com, under Events & Presentations on the investor relations page. Information related to the conference call will also be available on the investor relations page of the Company’s website.


Use of Non-GAAP measures

Adjusted EBITDA, as provided herein, represents net income (loss) from continued operations, adjusted for net interest expense, income taxes, depreciation and amortization expense, debt extinguishment, accelerated maintenance expense for new international deployments, goodwill or asset impairments and gains on bargain purchase acquisitions. Adjusted EBITDA is not a measure derived in accordance with GAAP. The Company presents Adjusted EBITDA as an additional measure by which to evaluate the Company’s operating trends. The Company believes that Adjusted EBITDA is a measure frequently used to evaluate performance of companies with substantial leverage and that the Company’s primary stakeholders (i.e., its stockholders, bondholders and banks) use Adjusted EBITDA to evaluate the Company’s period to period performance. Additionally, management believes that Adjusted EBITDA provides a transparent measure of the Company’s recurring operating performance and allows management and investors to readily view operating trends, perform analytical comparisons and identify strategies to improve operating performance. For this reason, the Company uses a measure based upon Adjusted EBITDA to assess performance for purposes of determining compensation under the Company’s incentive plan. Adjusted EBITDA should not be considered an alternative to, or more meaningful than, amounts determined in accordance with GAAP including: (a) operating income as an indicator of operating performance; or (b) cash flows from operations as a measure of liquidity. As such, the Company’s use of Adjusted EBITDA, instead of a GAAP measure, has limitations as an analytical tool, including the inability to determine profitability or liquidity due to the exclusion of accelerated maintenance expense for new international deployments, goodwill or asset impairments, gains on bargain purchase acquisitions, interest and income tax expense and the associated significant cash requirements and the exclusion of depreciation and amortization, which represent significant and unavoidable operating costs given the level of indebtedness and capital expenditures needed to maintain the Company’s business. For these reasons, the Company uses operating income to measure the Company’s operating performance and uses Adjusted EBITDA only as a supplement. Adjusted EBITDA is reconciled to net income attributable to common stockholders of Great Lakes Dredge & Dock Corporation in the table of financial results. For further explanation, please refer to the Company’s SEC filings.


The Company

Great Lakes Dredge & Dock Corporation (“Great Lakes” or the “Company”) is the largest provider of dredging services in the United States. In addition, the Company has a long history of performing significant international projects. The Company employs experienced civil, ocean and mechanical engineering staff in its estimating, production and project management functions. In its over 130-year history, the Company has never failed to complete a marine project. Great Lakes owns and operates the largest and most diverse fleet in the U.S. dredging industry, comprised of over 200 specialized vessels. Great Lakes has a disciplined training program for engineers that ensures experienced-based performance as they advance through Company operations. The Company’s Incident-and Injury-Free® (IIF®) safety management program is integrated into all aspects of the Company’s culture. The Company’s commitment to the IIF® culture promotes a work environment where employee safety is paramount.


Cautionary Note Regarding Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking” statements as defined in Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”), the Private Securities Litigation Reform Act of 1995 (the “PSLRA”) or in releases made by the Securities and Exchange Commission (the “SEC”), all as may be amended from time to time. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of Great Lakes and its subsidiaries, or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements that are not historical fact are forward-looking statements. Forward-looking statements can be identified by, among other things, the use of forward-looking language, such as the words “plan,” “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project,” “may,” “would,” “could,” “should,” “seeks,” “are optimistic,” or “scheduled to,” or other similar words, or the negative of these terms or other variations of these terms or comparable language, or by discussion of strategy or intentions. These cautionary statements are being made pursuant to the Exchange Act and the PSLRA with the intention of obtaining the benefits of the “safe harbor” provisions of such laws. Great Lakes cautions investors that any forward-looking statements made by Great Lakes are not guarantees or indicative of future performance. Important assumptions and other important factors that could cause actual results to differ materially from those forward-looking statements with respect to Great Lakes include, but are not limited to: impacts resulting from or attributable to the COVID-19 pandemic, our ability to obtain federal government dredging and other contracts; uncertainties in federal government budgeting; extended federal government shutdowns, which may lead to funding issues, the incurrence of costs without payment or reimbursement under our contracts, and delays or cancellations of key projects; the risk that the President of the United States may divert funds away from the Army Corps of Engineers in response to a national emergency; our ability to qualify as an eligible bidder under government contract criteria and to compete successfully against other qualified bidders; risks associated with cost over-runs, operating cost inflation and potential claims for liquidated damages, particularly with respect to our fixed cost contracts; the timing of our performance on contracts; significant liabilities that could be imposed were we to fail to comply with government contracting regulations; risks related to international dredging operations, including instability and declining relationships amongst certain governments in the Middle East and the impact this may have on infrastructure investment, asset value of such operations, and local licensing, permitting and royalty issues; increased cost of certain material used in our operations due to tariffs; a significant negative change to large, single customer contracts from which a significant portion of our international revenue is derived; changes in previous-recorded net revenue and profit as a result of the significant estimates made in connection with our methods of accounting for recognizing revenue; consequences of any lapse in disclosure controls and procedures or internal control over financial reporting; changes in the amount of our estimated backlog; our ability to obtain bonding or letters of credit and risks associated with draws by the surety on outstanding bonds or calls by the beneficiary on outstanding letters of credit; increasing costs to operate and maintain aging vessels; equipment or mechanical failures; acquisition integration and consolidation risks; impacts of legal and regulatory proceedings, including potential penalties and reputational damage as a result of such proceedings: unforeseen delays and cost overruns related to the construction of new vessels, including potential mechanical and engineering issues; our becoming liable for the obligations of joint ventures, partners and subcontractors; capital and operational costs due to environmental regulations; market and regulatory responses to climate change; our potential entry into the offshore wind market; unionized labor force work stoppages; increased costs associated with the transition and risks related to employee retention; maintaining an adequate level of insurance coverage; information technology security breaches; our substantial amount of indebtedness; restrictions imposed by financing covenants; the impact of adverse capital and credit market conditions; limitations on our hedging strategy imposed by statutory and regulatory requirements for derivative transactions; foreign exchange risks; changes in macroeconomic indicators and the overall business climate; and losses attributable to our investments in privately financed projects. For additional information on these and other risks and uncertainties, please see Item 1A. “Risk Factors” of Great Lakes’ Annual Report on Form 10-K for the year ended December 31, 2020, and in other securities filings by Great Lakes with the SEC.

Although Great Lakes believes that its plans, intentions and expectations reflected in or suggested by such forward-looking statements are reasonable, actual results could differ materially from a projection or assumption in any forward-looking statements. Great Lakes’ future financial condition and results of operations, as well as any forward-looking statements, are subject to change and inherent risks and uncertainties. The forward-looking statements contained in this press release are made only as of the date hereof and Great Lakes does not have or undertake any obligation to update or revise any forward-looking statements whether as a result of new information, subsequent events or otherwise, unless otherwise required by law.

   
Great Lakes Dredge & Dock Corporation  
Condensed Consolidated Statements of Operations  
(Unaudited and in thousands, except per share amounts)  
               
  Three Months Ended  
  March 31,  
    2021       2020  
Contract revenues $ 177,633     $ 217,695  
Gross profit   33,076       68,474  
General and administrative expenses   16,322       15,571  
(Gain) loss on sale of assets—net   106       (145 )
Operating income   16,648       53,048  
Interest expense—net   (6,586 )     (6,630 )
Other income (expense)   141       (1,121 )
Income before income taxes   10,203       45,297  
Income tax provision   (1,389 )     (11,310 )
Net income $ 8,814     $ 33,987  
               
Basic earnings per share $ 0.14     $ 0.53  
Basic weighted average shares   65,269       64,455  
               
Diluted earnings per share $ 0.13     $ 0.52  
Diluted weighted average shares   66,159       65,717  
               

Great Lakes Dredge & Dock Corporation  
Reconciliation of Net Income to Adjusted EBITDA  
(Unaudited and in thousands)  
               
  Three Months Ended  
  March 31,  
    2021       2020  
Net income $ 8,814     $ 33,987  
Adjusted for:              
Interest expense—net   6,586       6,630  
Income tax provision   1,389       11,310  
Depreciation and amortization   10,053       9,451  
Adjusted EBITDA $ 26,842     $ 61,378  
               

Great Lakes Dredge & Dock Corporation  
Selected Balance Sheet Information  
(Unaudited and in thousands)  
               
  Period Ended  
  March 31,     December 31,  
    2021       2020  
               
Cash and cash equivalents $ 177,708     $ 216,510  
Total current assets   349,677       362,693  
Total assets   959,982       958,024  
Total current liabilities   169,297       176,287  
Long-term debt   323,958       323,735  
Total equity   356,610       346,668  
               

Great Lakes Dredge & Dock Corporation
Revenue and Backlog Data
(Unaudited and in thousands)
     
  Three Months Ended  
  March 31,  
Revenues   2021       2020  
Dredging:              
Capital – U.S. $ 77,606     $ 83,549  
Capital – foreign   4,709       6,862  
Coastal protection   46,631       79,850  
Maintenance   45,301       42,385  
Rivers & lakes   3,386       5,049  
Total revenues $ 177,633     $ 217,695  
               

  As of  
  March 31,     December 31,     March 31,  
Backlog   2021       2020       2020  
Dredging:                      
Capital – U.S. $ 310,163     $ 320,920     $ 303,637  
Capital – foreign   2,077       6,865       23,896  
Coastal protection   82,589       97,986       76,786  
Maintenance   84,820       125,090       58,945  
Rivers & lakes   6,334       8,515       11,631  
Total backlog $ 485,983     $ 559,376     $ 474,895  
                       

For further information contact:

Tina Baginskis

Director, Investor Relations

630-574-3024



FOREWARN Partners with South Metro Denver REALTOR® Association

The 2nd largest local REALTOR® Association in the state of Colorado contracts to make FOREWARN services available for its 5,200+ REALTOR® members to promote proactive agent safety

BOCA RATON, Fla., May 04, 2021 (GLOBE NEWSWIRE) — FOREWARN, LLC, a red violet company (NASDAQ: RDVT) and the leading provider of real-time information solutions for real estate agents, today announced that the South Metro Denver REALTOR® Association (“SMDRA”) has contracted to make FOREWARN® services available for the 5,200+ REALTOR® members it serves throughout the Denver metro area to promote proactive real estate agent safety.

Available both online and through a mobile application, FOREWARN analyzes billions of data points and provides users with the ability to mitigate risks by verifying identity, searching for criminal histories, and validating information provided by potential clients — using just a phone number. FOREWARN allows agents to properly and safely plan for showings with a higher level of confidence.

The FOREWARN services purchased by SMDRA will be available to the 5,200+ real estate agent membership at no additional cost to individual agents.

“I am pleased to announce this partnership with FOREWARN to provide an added layer of proactive safety and intelligence for all our members,” said Brian Anzur, Chairman of South Metro Denver REALTOR® Association. “FOREWARN is a powerful tool that we feel is critical for our members’ safety and wellbeing. It is important that our members can quickly identify their prospects and potential risks well before they are in a vulnerable situation.”

Melissa Maldonado, CEO of South Metro Denver REALTOR® Association went on to say, “Working with unknown prospects is a regular occurrence for our members. Having FOREWARN at their fingertips is going to help them operate with greater peace of mind.”

On May 4, 2021, existing SMDRA members will receive specific instructions on how to move forward with activating their FOREWARN subscription.

All other real estate agencies and agents can learn more about FOREWARN at www.forewarn.com.

About FOREWARN®

At FOREWARN, we bring instant knowledge through innovative solutions to ensure safer engagements and smarter interactions. Leveraging powerful analytics and a massive data repository, our solutions enable organizations to gain real-time knowledge, for purposes such as verifying identity, searching for criminal histories, and validating information. Risk assessment and due diligence at your fingertips™.

RELATED LINKS:
www.forewarn.com

About red violet®

At red violet, we build proprietary technologies and apply analytical capabilities to deliver identity intelligence. Our technology powers critical solutions, which empower organizations to operate with confidence. Our solutions enable the real-time identification and location of people, businesses, assets and their interrelationships. These solutions are used for purposes including risk mitigation, due diligence, fraud detection and prevention, regulatory compliance, and customer acquisition. Our intelligent platform, CORE™, is purpose-built for the enterprise, yet flexible enough for organizations of all sizes, bringing clarity to massive datasets by transforming data into intelligence. Our solutions are used today to enable frictionless commerce, to ensure safety, and to reduce fraud and the concomitant expense borne by society. For more information, please visit www.redviolet.com.

FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipate,” “believes,” “should,” “intends,” “estimates,” and other words of similar meaning. Such forward looking statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations, including whether FOREWARN will provide an added layer of proactive safety and intelligence for SMDRA members and whether FOREWARN will assist SMDRA members to quickly identify their prospects and potential risks well before SMDRA members find themselves in a vulnerable situation. Readers are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release and are advised to consider the factors listed above together with the additional factors under the heading “Forward-Looking Statements” and “Risk Factors” in red violet’s SEC Filings. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Investor Relations Contact:

Camilo Ramirez
Red Violet, Inc.
561-757-4500
[email protected]



Neoleukin Therapeutics to Participate in BofA Securities 2021 Healthcare Conference

SEATTLE, May 04, 2021 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in a fireside chat during the BofA Securities 2021 Healthcare Conference on Wednesday, May 12, 2021 at 10:15 a.m. Eastern Time.

A live audio webcast of the corporate presentation and question and answer session to follow will be available from the investors section of the Neoleukin website at http://investor.neoleukin.com/events. An archived replay will also be available on the company website for at least 30 days following the event.

About Neoleukin Therapeutics, Inc.

Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins.  Neoleukin’s lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface. For more information, please visit the Neoleukin website: www.neoleukin.com.

Safe Harbor / Forward-Looking Statements

This press release contains “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the therapeutic properties and potential of the company’s de novo protein design technology, the results of the clinical trial for NL-201, and planned clinical and development activities and timelines. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. These statements are subject to numerous risks and uncertainties, including risks and uncertainties related to the company’s cash forecasts, the company’s ability to advance its product candidates, the receipt and timing of potential regulatory submissions, designations, approvals and commercialization of product candidates, the timing and results of preclinical and clinical trials, the timing of announcements and updates relating to the company’s clinical trials and related data market conditions and further impacts of COVID-19, that could cause actual results to differ materially from what Neoleukin expects. Further information on potential risk factors that could affect Neoleukin’s business and its financial results are detailed under the heading “Risk Factors” in documents the company files from time to time with the Securities and Exchange Commission (SEC), and other reports as filed with the SEC. Neoleukin undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contacts:

Media

Julie Rathbun
206-769-9219
[email protected]

Investors

Solebury Trout
Alexandra Roy
617-221-9197
[email protected]



Yumanity Therapeutics to Host Virtual R&D Day on Monday, May 17, 2021

BOSTON, May 04, 2021 (GLOBE NEWSWIRE) — Yumanity Therapeutics (NASDAQ: YMTX), a biopharmaceutical company focused on the development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that the Company will host a virtual R&D Day on Monday, May 17, 2021 at 12:00 p.m. ET. The event will feature presentations from external expert, David S. Russell, M.D., Ph.D., who specializes in movement disorders, dementias and other neurodegenerative diseases, and the Yumanity Therapeutics senior management team.

Presenters:

  • David S. Russell, M.D., Ph.D., Director, Clinical Research, Institute for Neurodegenerative Disorders; Assistant Clinical Professor, Yale School of Medicine; Senior Medical Director, Invicro, a Konica-Minolta Company
  • Richard Peters, M.D., Ph.D., President, CEO, and Director at Yumanity Therapeutics
  • Ajay Verma, M.D., Ph.D., Executive Vice President, Head of R&D at Yumanity Therapeutics
  • Brigitte Robertson, M.D., Chief Medical Officer at Yumanity Therapeutics
  • Daniel Tardiff, Ph.D., Scientific Co-Founder and Interim Head of Research at Yumanity Therapeutics

The live and archived webcast can be accessed under “Events & Presentations” in the Investor Relations section of the Company’s website at https://www.yumanity.com/investor-relations/events-presentations/. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.   A replay of the webcast will be available for 60 days following the event.

About Yumanity Therapeutics

Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company’s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson’s disease. Yumanity’s drug discovery platform is designed to enable the Company to rapidly screen for potential disease-modifying therapies by overcoming toxicity of misfolded proteins in neurogenerative diseases. Yumanity’s pipeline consists of additional programs focused on Lewy body dementia, multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), frontotemporal lobar dementia (FTLD), and Alzheimer’s disease. For more information, please visit www.yumanity.com.

Investors:

Burns McClellan, Inc.
Lee Roth
[email protected]
(212) 213-0006

Media:

Burns McClellan, Inc.
Ryo Imai / Robert Flamm, Ph.D.
[email protected] / [email protected]
(212) 213-0006



IPG Photonics Reports First Quarter 2021 Financial Results

Demand Recovery Strengthens, Driving Revenue of $346 Million and Earnings per Diluted Share of $1.26

Eugene A. Scherbakov to become CEO and Valentin P. Gapontsev to transition to Executive Chairman of the Board

OXFORD, Mass., May 04, 2021 (GLOBE NEWSWIRE) — IPG Photonics Corporation (NASDAQ: IPGP) today reported financial results for the first quarter ended March 31, 2021. In a separate press release, the Company announced CEO transition, which is effective immediately.

    Three Months Ended March 31,    

(In millions, except per share data and percentages)
  2021   2020   Change
Revenue   $ 345.6      $ 249.2      39  %
Gross margin   47.5  %   41.3  %    
Operating income   $ 88.8      $ 44.8      98  %
Operating margin   25.7  %   18.0  %    
Net income attributable to IPG Photonics Corporation   $ 68.1      $ 36.4      87  %
Earnings per diluted share   $ 1.26      $ 0.68      85  %

Management Comments

“We were pleased to see continued strong demand in China and North America as well as a further improvement in Europe. These drove both year-over-year and sequential increases in sales, despite typical seasonality, helping us achieve our best first quarter results since 2018, which was a record year, and a solid start to 2021,” said Dr. Valentin Gapontsev, IPG Photonics’ Executive Chairman of the Board. “We saw firm demand in welding applications, growth in electric vehicle battery production and solar cell manufacturing that helped our results. Initial orders for our handheld welder were strong and we are increasing production of this innovative device to meet growing customer demand,” said Dr. Eugene Scherbakov, IPG Photonics’ Chief Executive Officer.

Financial Highlights

First quarter revenue of $346 million increased 39% year over year. Materials processing sales increased 45% year over year due to higher sales in welding, cutting, solar cell manufacturing, sintering and ablation applications. Materials processing sales accounted for 92% of total revenue in the quarter. Sales into other applications decreased 9% year over year as strength in advanced applications and telecom was offset by lower revenue in medical.

Sales of high power continuous wave (“CW”) lasers, representing 49% of total revenue, increased 43% year over year. These sales benefited from growth of ultra-high power fiber lasers (6 kilowatts of power or greater), which represented 55% of all high power CW laser sales, as well as strong demand for pulsed and adjustable mode beam (AMB) lasers. By region, sales increased 104% in China, 14% in Europe, and 9% in North America on a year-over-year basis. Sales decreased 21% in Japan.

Earnings per diluted share (“EPS”) of $1.26 increased 85% year over year. Foreign exchange gains benefited EPS by $0.09. The effective tax rate in the quarter was 23%. During the first quarter, IPG generated $88 million in cash from operations. Capital expenditures were $27 million and stock repurchases totaled $3 million.

Business Outlook and Financial Guidance

“The broad-based economic recovery across most of our end markets supported strong bookings in the first quarter and resulted in a book-to-bill that was meaningfully above 1. I am encouraged to see strong bookings for our core high power fiber lasers used in cutting and welding applications as well as for newer emerging products in medical applications, electric vehicle battery production and solar cell manufacturing. We believe that global trends such as increasing energy efficiency and sustainability, displacement of legacy non-laser processes and growth in electric vehicle battery capacity, together with a recovery in global capital spending and improving economic conditions will continue to drive demand for our fiber lasers,” concluded Dr. Gapontsev.

For the second quarter of 2021, IPG expects revenue of $360 to $390 million. The Company expects the second quarter tax rate to be approximately 25%. IPG anticipates delivering earnings per diluted share in the range of $1.20 to $1.50, with 53.5 million basic common shares outstanding and 54.2 million diluted common shares outstanding. Financial guidance provided this quarter is subject to greater risk and uncertainty given the COVID-19 pandemic and its associated impacts to the global business environment, public health requirements and government mandates.

As discussed in more detail in the “Safe Harbor” passage of this news release, actual results may differ from this guidance due to various factors including, but not limited to, government and Company measures implemented to address the COVID-19 pandemic, product demand, order cancellations and delays, competition, tariffs, trade policy changes and general economic conditions. This guidance is based upon current market conditions and expectations, and is subject to the risks outlined in the Company’s reports with the SEC, and assumes exchange rates relative to the U.S. Dollar of Euro 0.85, Russian Ruble 76, Japanese Yen 111 and Chinese Yuan 6.57, respectively.

Supplemental Financial Information

Additional supplemental financial information is provided in the unaudited First Quarter 2021 Financial Data Workbook available on the investor relations section of the Company’s website at investor.ipgphotonics.com.

Conference Call Reminder

The Company will hold a conference call today, May 4, 2021 at 10:00 am ET. To access the call, please dial 877-407-6184 in the US or 201-389-0877 internationally. A live webcast of the call will also be available and archived on the investor relations section of the Company’s website at investor.ipgphotonics.com.

Contact

Eugene Fedotoff
Director of Investor Relations
IPG Photonics Corporation
508-597-4713
[email protected] 

About IPG Photonics Corporation

IPG Photonics Corporation is the leader in high-power fiber lasers and amplifiers used primarily in materials processing and other diverse applications. The Company’s mission is to make its fiber laser technology the tool of choice in mass production. IPG accomplishes this mission by delivering superior performance, reliability and usability at a lower total cost of ownership compared with other types of lasers and non-laser tools, allowing end users to increase productivity and decrease costs. A member of the S&P 500® Index, IPG is headquartered in Oxford, Massachusetts and has more than 30 facilities worldwide. For more information, visit www.ipgphotonics.com

Safe Harbor Statement

Information and statements provided by IPG and its employees, including statements in this press release, that relate to future plans, events or performance are forward-looking statements. These statements involve risks and uncertainties. Any statements in this press release that are not statements of historical fact are forward-looking statements, including, but not limited to, broad-based economic recovery, global trends such as increasing energy efficiency and sustainability, displacement of legacy non-laser processes and growth in electric vehicle battery capacity, a recovery in global capital spending and improving economic conditions that continue to drive demand for our fiber lasers, impacts of COVID-19 on our business, the global economy and government policies, revenue, tax rate and earnings guidance for Q2 2021. Factors that could cause actual results to differ materially include risks and uncertainties, including risks associated with the strength or weakness of the business conditions in industries and geographic markets that IPG serves, particularly the effect of downturns in the markets IPG serves; uncertainties and adverse changes in the general economic conditions of markets; IPG’s ability to penetrate new applications for fiber lasers and increase market share; the rate of acceptance and penetration of IPG’s products; inability to manage risks associated with international customers and operations; changes in trade controls and trade policies; foreign currency fluctuations; high levels of fixed costs from IPG’s vertical integration; the appropriateness of IPG’s manufacturing capacity for the level of demand; competitive factors, including declining average selling prices; the effect of acquisitions and investments; inventory write-downs; asset impairment charges; intellectual property infringement claims and litigation; interruption in supply of key components; manufacturing risks; government regulations and trade sanctions; and other risks identified in IPG’s SEC filings. Readers are encouraged to refer to the risk factors described in IPG’s Annual Report on Form 10-K (filed with the SEC on February 22, 2021) and IPG’s reports filed with the SEC, as applicable. Actual results, events and performance may differ materially. Readers are cautioned not to rely on the forward-looking statements, which speak only as of the date hereof. IPG undertakes no obligation to update the forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

IPG PHOTONICS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)

    Three Months Ended March 31,
    2021   2020
         
    (In thousands, except per share data)
Net sales   $ 345,585     $ 249,242  
Cost of sales   181,594     146,366  
Gross profit   163,991     102,876  
Operating expenses:        
Sales and marketing   18,883     18,683  
Research and development   33,339     31,838  
General and administrative   30,092     27,124  
(Gain) on foreign exchange   (7,165 )   (19,565 )
Total operating expenses   75,149     58,080  
Operating income   88,842     44,796  
Other (expense) income, net:        
Interest (expense) income, net   (495 )   3,073  
Other income, net   253     191  
Total other (expense) income   (242 )   3,264  
Income before provision of income taxes   88,600     48,060  
Provision for income taxes   20,378     11,294  
Net income   68,222     36,766  
Less: net income attributable to non-controlling interests   95     363  
Net income attributable to IPG Photonics Corporation common stockholders   $ 68,127     $ 36,403  
Net income attributable to IPG Photonics Corporation per common share:        
Basic   $ 1.27     $ 0.69  
Diluted   $ 1.26     $ 0.68  
Weighted average common shares outstanding:        
Basic   53,541     53,075  
Diluted   54,201     53,676  

IPG PHOTONICS CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

    March 31,   December 31,
    2021   2020
         
    (In thousands, except share and 

per share data)
ASSETS
Current assets:        
Cash and cash equivalents   $ 896,741     $ 876,231  
Short-term investments   548,196     514,835  
Accounts receivable, net   252,877     264,321  
Inventories   368,149     364,993  
Prepaid income taxes   70,421     69,893  
Prepaid expenses and other current assets   65,877     57,804  
Total current assets   2,202,261     2,148,077  
Deferred income taxes, net   41,276     43,197  
Goodwill   38,764     41,366  
Intangible assets, net   61,768     62,114  
Property, plant and equipment, net   600,911     597,527  
Other assets   37,971     43,419  
Total assets   $ 2,982,951     $ 2,935,700  
LIABILITIES AND EQUITY
Current liabilities:        
Current portion of long-term debt   $ 3,828     $ 3,810  
Accounts payable   44,704     25,748  
Accrued expenses and other current liabilities   162,775     176,740  
Income taxes payable   3,446     8,280  
Total current liabilities   214,753     214,578  
Deferred income taxes and other long-term liabilities   94,335     92,854  
Long-term debt, net of current portion   33,193     34,157  
Total liabilities   342,281     341,589  
Commitments and contingencies        
IPG Photonics Corporation equity:        
Common stock, $0.0001 par value, 175,000,000 shares authorized; 55,672,783 and 53,623,865 shares issued and outstanding, respectively, at March 31, 2021; 55,416,246 and 53,427,234 shares issued and outstanding, respectively, at December 31, 2020.   6     6  
Treasury stock, at cost, 2,048,918 and 2,034,012 shares held at March 31, 2021 and December 31, 2020, respectively.   (306,662 )   (303,614 )
Additional paid-in capital   868,097     854,301  
Retained earnings   2,256,318     2,188,191  
Accumulated other comprehensive loss   (178,257 )   (146,065 )
Total IPG Photonics Corporation equity   2,639,502     2,592,819  
Non-controlling interests   1,168     1,292  
Total equity   2,640,670     2,594,111  
Total liabilities and equity   $ 2,982,951     $ 2,935,700  

IPG PHOTONICS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

    Three Months Ended March 31,
    2021   2020
         
    (In thousands)
Cash flows from operating activities:        
Net income   $ 68,222     $ 36,766  
Adjustments to reconcile net income to net cash provided by operating activities:        
Depreciation and amortization   23,819     24,099  
Provisions for inventory, warranty and bad debt   16,685     13,486  
Other   6,421     (11,079 )
Changes in assets and liabilities that provided (used) cash, net of acquisitions:        
Accounts receivable and accounts payable   26,340     40,546  
Inventories   (20,084 )   (10,429 )
Other   (33,860 )   (36,608 )
Net cash provided by operating activities   87,543     56,781  
Cash flows from investing activities:        
Purchases of property, plant and equipment   (27,421 )   (17,801 )
Proceeds from sales of property, plant and equipment   130     139  
Purchases of short-term investments   (513,564 )   (308,195 )
Proceeds from short-term investments   480,163     186,024  
Other   (2 )   79  
Net cash used in investing activities   (60,694 )   (139,754 )
Cash flows from financing activities:        
Principal payments on long-term borrowings   (946 )   (928 )
Proceeds from issuance of common stock under employee stock option and purchase plans less payments for taxes related to net share settlement of equity awards   4,981     (5,498 )
Purchase of treasury stock, at cost   (3,048 )   (12,716 )
Payment of purchase price holdback from business combination   (2,624 )   (1,650 )
Net cash used in financing activities   (1,637 )   (20,792 )
Effect of changes in exchange rates on cash and cash equivalents and restricted cash   (7,024 )   (6,878 )
Net increase in cash, cash equivalents and restricted cash   18,188     (110,643 )
Cash, cash equivalents and restricted cash — Beginning of period   878,553     682,984  
Cash and cash equivalents — End of period   $ 896,741     $ 572,341  
Supplemental disclosures of cash flow information:        
Cash paid for interest   $ 703     $ 447  
Cash paid for income taxes   $ 21,340     $ 29,865  

IPG PHOTONICS CORPORATION

SUPPLEMENTAL SCHEDULE OF AMORTIZATION OF INTANGIBLE ASSETS (UNAUDITED)

    Three Months Ended March 31,
    2021   2020
         
    (In thousands)
Amortization of intangible assets:        
Cost of sales   $ 1,241     $ 1,222  
Sales and marketing   2,016     1,778  
Research and development       133  
Total amortization of intangible assets   $ 3,257     $ 3,133  

        

IPG PHOTONICS CORPORATION

SUPPLEMENTAL SCHEDULE OF STOCK-BASED COMPENSATION (UNAUDITED)

    Three Months Ended March 31,
    2021   2020
    (In thousands)
Cost of sales   $ 2,626     $ 2,532  
Sales and marketing   1,160     961  
Research and development   2,118     2,071  
General and administrative   2,949     2,874  
Total stock-based compensation   8,853     8,438  
Tax effect of stock-based compensation   (1,878 )   (1,936 )
Net stock-based compensation   $ 6,975     $ 6,502  

    Three Months Ended March 31,
    2021   2020
         
    (In thousands)
Excess tax benefit on exercise of stock options included in net income   $ 5,596     $ 2,918  



Announcing Herzberg50 and ‘NobelCanadian’

TORONTO, May 04, 2021 (GLOBE NEWSWIRE) — Defining Moments Canada/Moments Déterminants Canada, a heritage education organization, announced today its partnership with the Government of Canada (through Canadian Heritage and the National Research Council of Canada NRC), the University of Saskatchewan, and Esri Canada to lead a national commemorative project this year honouring the 50th Anniversary of Dr. Gerhard Herzberg’s Nobel Prize in Chemistry, which will develop into a full commemoration project honouring all of Canada’s Nobel Laureates in 2022-2023.

HERZBERG50 will spotlight Dr. Herzberg’s Nobel-Prize winning research, as well as celebrate his impact on science policy and education, and his remarkable life journey. This storytelling initiative will be enhanced by ‘NobelCanadian’, a digital space to recognize Canadian Nobel Laureates, their achievements, and their deep imprint on this country. “The team at Defining Moments Canada is honoured to commemorate the achievements of Canada’s Nobel Laureates over the next two years. Paying special tribute to the remarkable life of Dr. Gerhard Herzberg is emblematic of all our inspiring Nobel Prize recipients,” said Neil Orford, President of Defining Moments Canada. “Herzberg’s lifetime commitment to research defined a new standard for science education in Canada, and we are proud to inaugurate the ‘NobelCanadian’ project with Herzberg50 in 2021.”

With the support of our partners, Defining Moments Canada will draw from the extensive research and digital archives curated by National Research Council of Canada, the University of Saskatchewan, and other major academic and research institutions nationwide to host these bilingual national commemorative projects on its website. These projects will inspire young Canadians to discover the lives and contributions of those who led scientific innovation and achievement over the last century.

The commemoration will feature a digital mosaic of “micro-histories” and accompanying pedagogical tools to explore the impact of Herzberg’s research and his personal story. Schools, museums, academic institutions, and organizations associated with physics and chemistry education will have access to the site’s articles, lesson plans, digital tools, assets, and artifacts through our innovative story-mapping and ‘virtual exhibition’ models, which will be appropriate for use in virtual or in-person learning across Canada.

Funded through Canadian Heritage’s Celebration and Commemoration Program, the initiative will utilize digital pedagogy and media, with content based on our model for ‘Curatorial Thinking.’ Young learners will be encouraged to become ‘digital detectives,’ learning how to develop and share commemorative stories with their communities.

“To get youth interested in past events, we must ensure that they have access to learning tools adapted to their reality. The Government of Canada is proud to support this national commemorative project celebrating the 50th Anniversary of Dr. Gerhard Herzberg’s Nobel Prize in Chemistry. I hope that such a remarkable story and model will inspire a new generation of scientists.”
The Honourable Steven Guilbeault, Minister of Canadian Heritage

National Research Council of Canada is a major financial partner for Herzberg50.

“This year marks two important milestones for Canada and Germany: the 50th anniversary of Dr. Gerhard Herzberg’s Nobel Prize in Chemistry, and the 50th anniversary of the formal Canada-Germany Science and Technology collaboration,” says Mitch Davies, President of the NRC. “Dr. Herzberg was a world-renowned scientist who advanced knowledge and pushed boundaries in chemistry, physics, and astrophysics with his passion for excellence and scientific exploration as a professor in Germany, and then as a researcher at the NRC. The NRC is honoured to celebrate Dr. Herzberg’s legacy.”

The project will also be supported by archival and historical research from the University of Saskatchewan, Dr. Herzberg’s home for 10 research-intensive years.

“Herzberg’s work is a testament to the importance of fundamental research where transformative applications become evident over time,” said University of Saskatchewan President Peter Stoicheff. “I am proud that the University of Saskatchewan and Canada welcomed Herzberg and his wife when no other country or university did, and in the process, enabled him to undertake superb work on the journey to the Nobel Prize. His legacy is evident today in so many ways, including at the USask Canadian Light Source where scientists from across Canada and around the world continue to unravel the mysteries of atomic structure.”

Esri Canada is supporting Defining Moments Canada with its innovative ArcGIS mapping technology, which will be used to teach and commemorate the life and work of Dr. Herzberg and the Canadian Nobel Laureates.

“Esri Canada is proud to collaborate with Defining Moments Canada/Moments Déterminants Canada by bringing digital heritage into pan-Canadian K-12 education using twenty-first century tools and storytelling skills to celebrate the 50th Anniversary of Dr. Gerhard Herzberg’s Nobel Prize in Chemistry. Bringing our history alive in this way allows us all to celebrate the defining moments of our past with the technology of the current era.”
Jean Tong, Esri Canada K-12 Education Manager

Defining Moments Canada/Moments Déterminants Canada is a digital heritage and education company, leading innovative educational engagement and the commemoration of Canada’s history using twenty-first century tools and storytelling skills. It has previously carried out the national commemorations of the 1918-1920

Influenza Pandemic

in Canada and the 75

th

Anniversary of D-Day –

‘Juno75’

. In 2020, Defining Moments Canada began

‘Insulin100’

a three-year commemorative project to celebrate the 100

th

Anniversary for the Discovery of Insulin, and led the national digital commemoration for

VEDay75

, in partnership with Veteran’s Affairs Canada.

For more information, digital images or to set up an interview, please contact:

Neil Orford, President

Defining Moments Canada
[email protected]

Jenifer Terry, Executive Director

Defining Moments Canada
[email protected]



Olink announces first core lab running the Olink Explore platform in Europe, making it available for more researchers

UPPSALA, Sweden, May 04, 2021 (GLOBE NEWSWIRE) — Olink Holding AB (publ) (Nasdaq: OLK) today announced that its Olink® Explore 1536/384 platform is now available to researchers in Europe through the SciLifeLab National Genomics Infrastructure (NGI) and the Affinity Proteomics Uppsala unit at SciLifeLab Clinical and Immunological platform (APU) by their combined capability SciLifeLab Explore lab.

This is the first core lab in Europe certified to offer the Olink Explore platform, comprising four protein biomarker panels for cardiovascular and metabolic diseases, oncology, neurology and inflammation. The platform enables researchers to define protein signatures that provide meaningful insights into human biology and dynamic changes in health and disease.

Through the launch of Olink® Explore 1536 as kits earlier this year, laboratories are now able to set up the Olink Explore platform, providing additional analysis capacity to researchers.

“This will further democratize the use of Olink in line with our mission to accelerate proteomics together with the scientific community. The objective is to create a better understanding of the origin of the disease, provide earlier and more accurate diagnoses with individualized treatment and enable more efficient and safer drug development. The SciLifeLab laboratory in Uppsala is our first EMEA laboratory to adopt Olink Explore, demonstrating the importance of academic partners in pioneering the establishment of new technologies. We are proud to be their selected partner,” says Jon Heimer, CEO of Olink.

By combining Olink’s patented proximity extension assay (PEA) technology with a high-throughput next generation sequencing (NGS) readout on Illumina® NovaSeq and NextSeq instruments, close to 1,500 protein biomarker targets can be measured simultaneously in only a few microliters of biological sample, providing clinically relevant, actionable insights. This year, Olink plans to increase the library to approximately 3,000 protein biomarker targets.

The PEA technology is based on two matching antibodies binding to the target protein. When the complementary DNA tags from the two antibodies come into close proximity, the tags hybridize and are extended making a unique DNA barcode for each analyzed protein. After amplification, digital DNA counting is performed using NGS and the resulting counts represent the concentration of the protein in the sample.

This project has been made possible by grants from SciLifeLab and the Swedish Research Council’s Access to Infrastructure and by building a new joint-capability lab between NGI and APU at the Biomedical Centre (BMC) in Uppsala.

“We are proud that SciLifeLab will be the first certified service provider offering this technology for the Swedish research community and believe this is a first step enabling integrated multi-omics analyses in precision medicine,” says SciLifeLab Scientific Director Staffan Svärd (Uppsala University, UU).

The project’s main applicant SciLifeLab researcher Ulf Gyllensten (UU) continues: “We believe that an entity like SciLifeLab really can contribute to the concept of precision medicine in many ways and we feel confident that the SciLifeLab Explore lab will deliver important results to users working with different medical issues. By combining the phenotype data with data from the human genome we can find and define new biomarkers. Since the sequencing is already in place at NGI, we will now aim to develop methods for simultaneous large-scale analysis of protein, DNA, and RNA.” 

For more information on setting up Olink Explore in your facility, please contact:
Andrea Ballagi
Email: [email protected]
Tel: +46708200635

Olink® Explore 1536 as kits offers high-multiplex proteomics with unmatched quality and throughput, which can deliver up to 1.3M protein measurements per week per NovaSeq instrument. Olink is also extending the flexibility of the platform by enabling screening of both the entire protein library and the four individual 384-plex panels that make up the library. The disease/biological process-focused panels are: Olink® Explore 384 Cardiometabolic, Olink® Explore 384 Inflammation, Olink® Explore 384 Neurology and Olink® Explore 384 Oncology.

More information about these panels is available – HERE

About Olink

Olink Holding AB (publ) (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The company was founded in 2016 and is well established across Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden. For more information, please visit www.olink.com